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All religions, arts and sciences are branches of the same tree.  
All these aspirations are directed toward ennobling man's life,  
lifting it from the sphere of mere physical existence  
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1. Introduction 
1.1 Psychiatric diseases 
1.1.1 Schizophrenia 
In 1908 Eugen Bleuler created the name “schizophrenia” for a severe psychiatric disease that 
lay people often associate with a split personality (WHO, 2006), reminiscent of the phrase in 
Goethe’s Faust “Two souls alas! are dwelling in my breast” (von Goethe, 1808), and Robert 
Louis Stevenson’s novel “Strange Case of Dr. Jekyll and Mr. Hyde” (Stevenson, 1886). In a 
schizophrenic person, however, the personality is not split into different parts: Schizophrenic 
people suffer from a misperception of reality, have problems to control their emotions, to 
think clearly, and to communicate, the latter owing to disorganization of their speech and 
thinking (WHO, 2006). Very typical symptoms include hearing of imaginary voices that 
control their thoughts and actions, and the belief that other people want to harm them (ibid). 
The manifestations are classified into negative and positive symptoms, whereas the term 
“positive” does not mean that the symptoms are good for the patient. Moreover, the term 
refers to the fact that such symptoms are exaggerations of behavior otherwise considered 
normal. “Positive symptoms”, including hallucinations, delusions, and thought disorders, are 
easily recognizable by relatives, and increase the patient’s response to medicine (ibid). In 
contrast, “negative symptoms” describe conditions that are decreased or attenuated compared 
to normal state, and are exhibited by lack of motivation, energy, experience of pleasure, 
attention, and concentration (ibid). The Greek roots of “schizophrenia” - skhizein (σχίζειν, "to 
split") and phrēn, or phren- (φρήν, φρεν-; "mind") – make sense when these contrasting 
symptoms in a schizophrenic person are apparent.  
The onset of symptoms usually occurs in young adulthood, with men usually 
manifesting their first symptoms no later than their 25th year, and women showing a delayed 
and smaller increase, followed by a second peak at the age of 45-79 years (Hafner et al., 
1993). Considering the variations in the distribution of schizophrenia, around 1% of the 
population is affected (Goldner et al., 2002) and the number of new cases per year, called 
incidence, represents around one among 10,000 people (Jablensky, 1995). The risk of suicide 
is around 5%, mainly committed at the beginning of the diagnosis (Palmer et al., 2005). About 
45% of the patients recover after one or more episodes, about 20% show continuing 
symptoms and increasing disability, and about 35% exhibit a mixed pattern, with varying 
degrees of remission and aggravation of different lengths (Barbato, 1998).  
I  Introduction 
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The causes of schizophrenia are multifactorial: biological, psychological and 
environmental factors contribute to the onset of schizophrenia. Living in an urban area 
increases the risk of schizophrenia (van Os, 2004; van Os et al., 2005), as well as social 
disadvantages such as poverty (Mueser and McGurk, 2004), and migration because of social 
adversity, unemployment, racial discrimination or family dysfunction (Selten et al., 2007). 
Furthermore, prenatal exposure to infections (Brown, 2006) stands in correlation to later 
development of schizophrenia. Polygenetic influence contributes with 5% to the manifestation 
of schizophrenia. The fact that a twin of a schizophrenic person only shows a risk of 45%, and 
not 100%, proves that apart from heritability, there are other external factors which contribute 
to onset of the disorder (O'Donovan et al., 2003).  
In schizophrenic patients, part of the neurons that use dopamine as neurotransmitter 
are hyperactive in psychoses, others are hypoactive which explains the occurrence of both 
positive and negative symptoms. Positive symptoms comprise conditions that are exaggerated 
compared to the standard state of health, namely delusions, hallucinations, thought disorder in 
form and content, misperception, and akathisia (psychomotoric agitation). By contrast, 
negative symptoms are described as limitation of normal experience, i.e. lack of motivation, 
flattening of affect, cognitive and motoric deficits including non-understanding of complex 
coherences, and reduction of mimic and gestures. Despite dysfunction of dopamine in the 
mesolimbic pathway of the brain, which involves dopamine D2-receptors, glutamate also 
seems to play an important role in schizophrenia. Patients demonstrate a lower activity of the 
N-Methyl-D-Aspartate (NMDA) glutamate receptor and there are low levels of the receptor in 
post mortem brains of patients diagnosed with schizophrenia (Konradi and Heckers, 2003). 
People suffering from schizophrenia receive a treatment composed of psychotherapy 
and antipsychotic drugs. Former so-called typical antipsychotic drugs act as dopamine 
antagonists and cause undesired effects of the extrapyramidale system: movement disorder, 
mainly in face and extremities, also called dyskinesia, parkinson-like symptoms and 
movement agitation (akathisia). These extrapyramidale side effects are especially critical 
when they appear after a long-standing therapy, and remain even after discontinuation of the 
corresponding drug. Newer so-called atypical neuroleptics are not only dopamine antagonists, 
but partly also dopamine agonists and furthermore influence the serotonin metabolism. By 
acting more specifically they reduce the side effects due to undesired blockade of dopamine 
receptors. They decrease the extrapyramidale side effects, but induce weight gain, and 
increase the risk of diseases related to obesity (Lieberman et al., 2005). As typical 
antipsychotic drugs cause a deficit of oestrogene, which might favor infertility and 
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osteoporosis, women are favorably treated with atypical antipsychotics. Furthermore, there 
are first evidences that the additional treatment of both female and male patients with 
oestrogens improves symptoms of schizophrenia (Kulkarni, 2009), thereby offering a possible 
novel treatment. 
Patients with schizophrenia often feature additional diseases such as major depression 
and anxiety disorders (Sim et al., 2006), and symptoms as well as treatment of the diseases are 
overlapping. 
 
1.1.2 Major depressive disorder 
There are different states of depression, and the term major depressive disorder was chosen by 
the American Psychiatric Association to describe a mental disorder of high severity that is 
characterized by low mood, feelings of worthlessness and hopelessness, incapability to feel 
pleasure in doing formerly enjoyable activities, and thoughts of death or suicide (American 
Psychiatric Association, 2000). Common accompanying symptoms are sleeping problems, 
decreased appetite, headache or digestive problems (ibid), and the impairment of patients to 
lead normal lives results in enormous costs of lost productive work time (American 
Psychiatric Association, 2000; Stewart et al., 2003). 
If we neglect the fact that there are geographical differences in the distribution of 
people with major depression, and if we take into consideration that different cultures have 
different definitions of the term “depression”, the lifetime prevalence to suffer from a major 
depressive episode lies between 8 and 10% in most countries (Kessler et al., 2005). Mood 
disorders are common disorders, and include major depression and bipolar disorders (see 
1.1.3). They are widely distributed with a life prevalence of up to 20% (Kessler et al., 2003).  
Most commonly, people contract major depression between 30 and 40 years or between 50 
and 60 years of age (Rickards, 2005). Compared to men, the number of women with major 
depression is elevated. Women show more suicide attempts, whereas men complete suicide 
more often (Oquendo et al., 2007). The average suicide rate of patients with major depression 
is 3.4%, with 7% in men and 1% in women (Blair-West and Mellsop, 2001). Amongst all 
cases of suicide, 60% are due to major depression (Barlow and Durand VM, 2005). 
Investigations of the causes of major depression are still ongoing. Psychological, 
social, and biological causes have been discussed so far (Surgeon General, 1999). Joblessness 
and poverty are contributors to onset of major depression (Weich and Lewis, 1998). 
According to a Swedish study, the genetic influence is 40% in women and 30% in men 
(Kendler et al., 2006). There seems to be a variant in the serotonin transporter gene which 
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increases the chances of depression after having been exposed to a stressful incident (Caspi et 
al., 2003).  
The monoamine hypothesis of depression signifies the involvement of the 
neurotransmitters serotonin, noradrenaline and dopamine in the manifestation of depression. 
The deficiency of one of these neurotransmitters causes the respective depressive characters. 
So noradrenaline is said to be associated with alertness and energy as well as anxiety, 
attention, and interest in life; decreased levels of serotonin stand in correlation with anxiety, 
obsession, and compulsion, whereas dopamine is assigned to attention, motivation, pleasure, 
reward, and interest in life (Nutt, 2008). Low serotonin levels lead to low levels of 
noradrenaline, and thus cause the onset of depression (Shah et al., 1999). 
The monoamine hypothesis is basis for the treatment of major depression that varies 
according to the symptoms of the single patient. Anxious people are mainly treated with drugs 
that increase the levels of serotonin and noradrenaline, whereas in patients with loss of energy 
and enjoyment of life as dominating symptoms of depression, drugs that lead to an increase in 
dopamine and noradrenaline levels are indicated. However, there are also antidepressant 
drugs, such as opipramol, that do not influence the monoamine system. A publication by the 
Public Library of Science revealed that the theory of the monoamine hypothesis had been  
presented in a far too simple and basic manner before the lay public, with the alleged purpose 
of increasing its chances of commercialization (Lacasse and Leo, 2005).  
There is a correlation between depression and decreased hippocampal neurogenesis 
(Mayberg, 2007). The hippocampus is a centre for mood and memory, and drugs that increase 
the serotonin level in the brain, such as SSRIs, stimulate neurogenesis in this area of the brain, 
leading to an increase in mass, and improvement of mood and memory (Duman et al., 1997; 
Sheline et al., 2003). Brain-derived neurotrophic factor (BDNF) is responsible for 
neurogenesis, and has been found to be three times more decreased in blood plasma of 
patients with major depression (Sen et al., 2008). Antidepressant drugs, in return, achieved to 
increase the BDNF plasma levels again (ibid). 
Another cause for major depression might be overactivity of the hypothalamic-
pituitary-adrenal axis (HPA axis), as increased cortisol levels and augmented pituitary and 
adrenal glands in depressive patients suggest. These findings reveal that the endocrine system 
is impaired in patients with major depressive disorder.  
The two main pillars of treatment in major depressive disorder are antidepressant 
drugs and psychotherapy. While the recent increase in treatment is encouraging, inadequate 
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treatment is a serious concern. Antidepressant treatment involves amelioration of symptoms 
over the course of weeks or months, and remains ineffective in many patients. 
In the past, the standard medication was dominated by tricyclic antidepressants that 
inhibit the reuptake of noradrenaline, dopamine and serotonin in a not very selective way. 
They have now taken a back seat because of their side effects such as obstipation, drop in 
blood pressure, fatigue, increased risk of intoxication. The main side effect, however, is the 
increased risk of suicide of some drugs in the beginning of the medication because they first 
improve motivation and only later brighten the mood of patients. Nowadays, selective 
serotonin reuptake inhibitors (SSRIs) are the first class drugs that have moderate side effects 
and show less toxicity after overdosage (Royal Pharmaceutical Society of Great Britain, 
2008). Suicide by overconsumption of tablets is impossible as SSRIs lead to emesis by 
stimulation of the serotonin 5HT3 receptor in the area postrema. 
Alternatives in case of non-responsiveness are the noradrenaline and dopamine 
reuptake inhibitor (NDRI) bupropion, the serotonin-noradrenaline reuptake inhibitor (SNRI) 
venlafaxine (Rush et al., 2006), and the neuroleptic drug olanzapine (Kruger, 2006). Lithium 
is also very frequently used in case of therapy resistance (Bschor and Bauer, 2006) or in acute 
manic episodes, but needs to be supervised very carefully as the therapeutic index is quite 
narrow, which means that effect and toxicity are close to each other. Only around 40% of 
patients respond to treatment with lithium.  
Worth mentioning are first electroconvulsive therapy in patients with very severe 
episodes of major depression, despite its side effects of memory loss, disorientation and 
headache (Barlow and Durand VM, 2005), and second St. John's wort in patients with light 
depression (Linde et al., 2008).  
Medication with antidepressive drugs should always be accompanied by 
psychotherapy, similar effective to SSRIs in case of mild and severe depressive symptoms. 
General physical activity has also been shown to improve symptoms in low-to-moderate 
depression (Martinsen, 2008). Furthermore, the associations between elevated serotonin levels 
during waking state and influence of light render sleep deprivation and light therapy 
promising approaches in the treatment of major depression (Adrien, 2002; Terman, 2007). 
 
1.1.3 Bipolar disorder 
Bipolar disorder is characterized by episodes of unnaturally elevated mood, called 
mania, or in cases of mild symptoms hypomania. Patients usually also show episodes of 
depression or mixed phases, and there are intermittent episodes of normal mood. If four or 
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more episodes of major depression, mania, hypomania, or a mixed type occur during one 
year, the term, “rapid cycling” is used (Mackin and Young, 2004). Changes in mood within 
24-48 hours are called “ultra-ultra rapid cycling”.  
There are different forms of bipolar disorders, dependent of symptoms and their 
frequency and intensity. The forth version of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR) classifies four types: Bipolar I disorder is characterized by at least 
one manic episode without necessarily requiring an episode of major depression. Patients with 
Bipolar II disorder, in contrast, show rather periods of hypomania than mania, and one or 
more episodes of major depression. A hypomanic episode is often identified as a highly 
productive and creative phase which complicates the diagnosis of Bipolar II. In cyclothymia, 
several hypomanic phases alternate with depressive episodes that are not classified as major 
depression. Patients show moderate changes in mood and are able to work. Bipolar Disorder 
Not Otherwise Specified (NOS) includes patients who don’t belong to one of the above 
mentioned categories.  
The lifetime prevalence for Bipolar Disorder I is estimated as 1%, 1.1% for Bipolar 
Disorder II and 2.4% for subthreshold symptoms (Merikangas et al., 2007). Onset of 
symptoms typically occurs during late adolescence and young adulthood (Christie et al., 
1988). The incidence of bipolar disorders is difficult to determine, mainly because doctors 
diagnose children more frivolously (Moreno et al., 2007) and because of general 
overdiagnosis in the USA (Carlson and Meyer, 2006; Harris, 2005; McClellan, 2005). 
Patients diagnosed with bipolar disorder commit suicide with a percentage of 15 to 19% (de 
Abreu et al., 2009). 
That people with bipolar disorder can lead normal and fulfilling lives depends on a 
correct diagnosis and adequate medication that should be continued during episodes of 
recovery to prevent relapses. The prognosis is very good if the patient has a good knowledge 
and awareness of his own disease, if he cooperates with a competent doctor and a trustful 
psychotherapist, if he possesses a good health condition that also comprises sports and healthy 
nutrition as well as avoidance of stress, and if he reacts adequately when he recognizes a 
change in his mood, activity or sleeping behavior. Functioning is mainly impaired during 
depressive episodes, whereas hypomania leads to amelioration (Judd et al., 2005). Famous 
examples of patients with bipolar disorder are the painter Vincent van Gogh and the 
composer, Robert Schumann, who were very successful during their manic phases. 
It has been shown that there exists a correlation between bipolar disorder and eating 
disorder. Many patients with bipolar disorder suffer from binge eating and have a higher body 
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mass index (BMI), waist circumference and fasting blood glucose levels (Castrogiovanni et 
al., 2009). 
Many causes are discussed that lead to the onset of bipolar disorder. There is a genetic 
influence demonstrated by a study in which the subtype Bipolar I was found with a 
correspondence of 40% in identical twins, and with 0-10% in fraternal twins (Kieseppa et al., 
2004). In a recent review, genes regarding the neurotransmitters dopamine (DRD4 and 
SLC6A3), serotonin (SLC6A4 and TPH2), glutamate (DAOA and DTNBP1) as well as genes 
related to pathways for cell growth (BDNF, NRG1 and DISC1) were found to be involved in 
the causes of bipolar disorder. The heritability as a whole is estimated to be 0.71% (Edvardsen 
et al., 2008). Environmental factors also play a role; abuse and trauma during childhood were 
found to be in correlation with an earlier onset of symptoms, an unfavorable progress and 
higher comorbidity.  
The medication is based on mood stabilizers, among which lithium carbonate and 
lamotrigine are the most successful (Bauer and Mitchner, 2004; Geddes et al., 2004). Whereas 
lamotrigine is effective in preventing depression, lithium lowers suicide rates to an extent of 
success far exceeding that of other tested drugs. Other commonly used mood stabilizers are 
sodium valproate and carbamazepine, the latter being successfully used in the treatment of 
rapid cycling. Atypical antipsychotic drugs are often needed to medicate manic phases. 
Olanzapine and quetiapine have been shown to successfully maintain bipolar disorder in 
monotherapy (Lilly, 2009), whereas the efficacy and safety of olanzapine even seem 
comparable to that of prophylactic therapy with lithium (Lilly, 2009; Tohen et al., 2005). As 
antidepressants can not only trigger episodes of (hypo)mania and mixed phases, but also can 
provoke rapid cycling if used without mood stabilizer, they must be applied very carefully 
(Sachs et al., 2007). The value of treatment without antidepressants was shown in a study in 
2007 when a mood stabilizer was shown as effective as an antidepressant (Bower, 2007). As 
in other psychiatric disorders, psychotherapy supports a positive course of the disease, and 
helps to maintain remission. 
 
The high risk of suicide in schizophrenia (10-15%), depression (3-4%) and bipolar 
disorder (15-19%), the enormous costs for the government and the impaired quality of life of 
the patients and their families justify the effort for extensive studies and huge effort to 
improve the understanding of these disorders, and to offer new possibilities for their 
treatment, mainly by investigating additional targets for novel drugs. The fact that brain-
derived neurotrophic factor (BDNF) is involved in schizophrenia (Gratacos et al., 2007; 
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Ivleva et al., 2008), depression (Sen et al., 2008) and bipolar disorder (Serretti and Mandelli, 
2008) advises the investigation of the phosphatidylinositol 3-kinase (PI3K) pathway, which is 
activated by BDNF.  
 
1.2 The PI3K pathway 
Insulin leads to the conversion of glucose to glycogen in skeletal muscle via stimulation of 
glucose uptake and via activation of glycogen synthase (GS). Activated GSK-3 
phosphorylates GS on four serine residues (Ser641, Ser645, Ser649, and Ser653) and 
therefore inactivates GS (Fig.1). As insulin causes the inhibition of GSK-3, it renders GS 
active. Besides the above mentioned serine residues, Ser7 is dephosphorylated by insulin in a 
GSK-3-independent way (McManus et al., 2005). Insulin also might stimulate GS via 
activation of a muscle glycogen-associated protein phosphatase (PP1) that reverses the 
phosphorylation of the GS serine residues by GSK-3 (Delibegovic et al., 2003; Suzuki et al., 
2001). In the liver, GS is mainly regulated by blood glucose levels (McManus et al., 2005). 
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Figure 1: Insulin signaling in the PI3K-pathway leads to inhibition of GSK-3 and formation of glycogen 
 
When insulin binds to the insulin receptor in liver, muscle and adipose tissue, it induces the 
phosphorylation of insulin-receptor-substrate (IRS) proteins and attracts them to the plasma 
membrane. IRS proteins become tyrosine-phosphorylated and, then, attract PI3K to the 
plasma membrane. The latter converts the membrane component phosphatidylinositol 4,5-
bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a reaction that is 
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reversed by the phosphatase PTEN. PIP3 serves as an anchor for both protein kinase B (PKB), 
also termed Akt, and 3-phosphoinositide-dependent protein kinase-1 (PDK1) (Cantley, 2002). 
The co-localization of those two kinases at the plasma membrane facilitates the 
phosphorylation of PKB by PDK (Beaulieu et al., 2009; Frame and Cohen, 2001). The 
complete activation of PKB requires phosphorylation of both PDK1 at Thr308 and 
PDK2/rictor-mTOR at Ser473 (Beaulieu et al., 2009). Activated PKB phosphorylates GSK-3 
at Ser21 in the isoform GSK-3α and at Ser9 in GSK-3ß (Fig.1). The phosphorylated sequence 
of GSK-3 then interacts with the substrate recognition motif on the GSK-3 kinase domain, 
thus preventing the binding of GSK-3 substrates and consequently inhibiting GSK-3 (Cross et 
al., 1995; McManus et al., 2005; Shaw et al., 1997). 
PIP3 also stimulates the phosphorylation of p70 ribosomal S6 kinase (S6K), which 
then enhances the ability of PDK1 to phosphorylate and activate S6K (Biondi et al., 2001).  
90-kDa ribosomal S6 kinase (RSK) is activated by phosphorylation of ERK/MAPK which 
requires phosphorylation of the T-loop residue of its N-terminal kinase domain by PDK1 
(Frodin et al., 2000).  
Serum- and glucocorticoid-inducable kinase (SGK) acts in a very similar way as PKB 
due to homology in the catalytic domain. One difference is, however, the missing plecktrin 
homology (PH) domain that exists in PKB but not SGK1. Accordingly, SGK1 is also able to 
inhibit GSK-3 by phosphorylation of the same serine residues PKB interacts with (Sakoda et 
al., 2003; Wyatt et al., 2006). 
 
1.3 The role of PDK1 
PDK1 is known to play an important role in insulin and growth factor signaling pathways, and 
thus mediates the effects of kinases involved in these pathways on cell growth, proliferation, 
survival and regulation of metabolism (Mora et al., 2004). PDK1 acts as a master kinase and 
regulates more than 23 protein kinases of the AGC (cAMP-dependent, cGMP-dependent and 
protein kinase C) kinase family. PDK1 signal transduction involves several related 
serine/threonine protein kinases including isoforms of protein kinase B (PKB/Akt) (Dummler 
and Hemmings, 2007; Whiteman et al., 2002), the p70 ribosomal S6 kinase (S6K) (Dann et 
al., 2007), the serum- and glucocorticoid-inducable protein kinase (SGK) (Lang et al., 2006a), 
the p90 ribosomal S6 kinase (RSK) (Hauge and Frodin, 2006), and protein kinase C (PKC) 
(Newton, 2003).  
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It is known that PDK1 exists in a single isoform and that only a single gene encodes 
PDK1 in mammals (Lawlor et al., 2002). PDK1 is ubiquitously expressed in cells and 
constitutively active (Bayascas, 2008; Peifer and Alessi, 2008). It possesses two regulatory 
domains: first, a Pleckstrin Homology (PH) domain, which binds to the phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) and is important for activation of PKB isoforms, and, second, the 
PDK1-interacting fragment (PIF) pocket, by which PDK1 interacts with all its other substrates 
of the ACG kinase family, except for PKB (Bayascas, 2008). 
Furthermore, PDK1 and its downstream signaling molecules, PKB and S6K, are 
involved in tumorigenesis. PTEN is the lipid phosphatase that reverses the effect of PI3K and 
breaks down PIP3 to PIP2. Frequent mutations of PTEN occurred in human cancer, and mice 
with one defective allele of PTEN (PTEN+/-) develop different kinds of tumors (Bayascas et 
al., 2005; Salmena et al., 2008). When PDK1 was decreased in these mice, the development 
of tumors could be significantly reduced, which means that PDK1 inhibitors are a valuable 
therapeutic in the treatment of cancer.  
 
1.4 The role of GSK-3 
Glycogen synthase kinase-3 (GSK-3) was originally discovered as a kinase that plays a 
crucial role in the glycogen metabolism in sceletal muscle, and leads to the formation of 
glycogen by phosphorylating and thus inhibiting glycogen synthase (GS). GSK-3 is 
constitutively active and ubiquitously expressed in mammalian tissue (Prickaerts et al., 2006). 
There are two isoforms of GSK-3, GSK-3α (51 kDa) and GSK-3ß (47 kDa), whose sequence 
similarity within the kinase catalytic domains is 97%. They are encoded by different genes, 
and GSK-3ß is more enriched in the nervous system. The main difference of the two isoforms 
consists in the extended N-terminal glycine-rich tail of GSK-3α (Frame and Cohen, 2001). 
Besides its main role in glucose and glycogen homeostasis, GSK-3 is also implicated in 
protein metabolism, cell proliferation, cell differentiation and apoptosis (Beurel and Jope, 
2006; Cohen and Frame, 2001; Frame and Cohen, 2001). GSK-3 is therefore involved in 
several non-psychological and psychological diseases such as diabetes, cancer, inflammation, 
Alzheimer’s disease, schizophrenia, attention-deficit-hyperactivity disorder (ADHD), and 
bipolar disorder. 
GSK-3 is inhibited via the phosphatidylinositol 3-kinase (PI3K)-dependent protein 
kinase B (PKB) pathway, the mitogen-activated protein kinase (MAPK) cascade and the 
mTOR pathway, whereas this study concentrates on the inhibitory effect of PI3K/PKB.  
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GSK-3 is also inhibited by the Wnt signaling pathway that includes a complex of Axin, ß-
catenin and GSK-3 (Frame and Cohen, 2001). Furthermore, there are direct inhibitors of 
GSK-3 such as LiCl and SB 216763 and SB 415286 (ibid).  
Because of its constitutional activity, GSK-3 continually has an effect on its substrates, 
and via phosphorylation keeps them in an inactive state or leads to their degradation. Besides 
its most famous substrate, the signaling molecule glycogen synthase (GS), GSK-3 interacts 
with several transcription factors, such as ß-catenin, Cyclin D1, Jun, Myc, cAMP-response-
element-binding protein (CREB), microphthalmia-associated transcription factor (MITF), 
nuclear factor of activated T-cells c (NFATc), CCAAT/enhancer binding proteins α and ß 
(C/EBPα and C/EBPß), and heat-shock factor-1 (HSF-1). GSK-3 also influences eukaryotic 
translation initiation factor 2B (eIF2B) and structural proteins, such as tau. Within the already 
mentioned Wnt-signaling pathway, GSK-3 phophorylates and stabilises axin, leading to the 
attraction of ß-catenin, it degrades ß-catenin by its phosphorylation, and via interaction with 
APC it facilitates the binding of the latter to ß-catenin and decreases binding of APC to 
microtubules. The influence of GSK-3 in protein synthesis is conducted via inhibition of 
eIF2B (Frame and Cohen, 2001; Wada, 2009b).  
 
1.5 The role of the PI3K pathway in psychiatric disorders 
Besides its role in diabetes, cancer, and inflammation (Eldar-Finkelman et al., 1999; Farina et 
al., 2009; Jope et al., 2007; Lee and Kim, 2007), GSK-3 has been implicated in a number of 
psychiatric disorders, including Alzheimer’s disease, schizophrenia, attention-deficit- 
hyperactivity disorder (ADHD), and bipolar disorder (Emamian et al., 2004; Lang et al., 
2007; Manji et al., 2003; Prickaerts et al., 2006; Van Wauwe and Haefner, 2003). Hyperactive 
GSK-3ß stands in correlation to insulin resistance, diabetes mellitus, tumorigenesis, 
inflammation, as well as neuropsychiatric and neurodegenerative disorders (Jope et al., 2007; 
Jope and Johnson, 2004; Wada et al., 2005a; Wada et al., 2005b; Wada, 2009a). 
There are several classical therapeutics that influence the activity of GSK-3. Amongst 
neuropsychiatric drugs, d-fenfluramin, which stimulates serotonin secretion and inhibits its 
reuptake, fluoxetin, a selective serotonin-reuptake inhibitor (SSRI), and imipramin, a tricyclic 
antidepressant, which blocks the reuptake of serotonin and noradrenaline, have been shown to 
increase the Ser9-phosphorylation of GSK-3ß (Li et al., 2004). Serotonin was found to 
regulate GSK-3 in both directions, as 5-HT1 receptors increase and 5-HT2 receptors decrease 
the Ser9-phosphorylation of GSK-3ß. In such disorders as depression, anxiety or 
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schizophrenia that exhibit a disequilibrated serotonin activity, GSK-3ß activity might, 
therefore, be impaired.  
When injected over a period of up to 28 days, haloperidol and risperidone, both 
classical antipsychotic drugs, as well as the first of the atypical antipsychotics clozapine 
increased GSK-3α/ß and ß-catenin levels. Raclopride, a D2-dopamine-receptor antagonist, has 
similar effects and lets us assume that antipsychotic drugs lead to the elevation of GSK-3α/ß 
and ß-catenin levels via inhibition of the D2-dopamine-receptor (Alimohamad et al., 2005a; 
Alimohamad et al., 2005b). 
In the treatment of Alzheimer’s disease, physostigmine, an acetylcholinesterase 
inhibitor, as well as memantine, an N-methyl-D-aspartate-receptor antagonist, led to elevated 
levels of Ser21/Ser9-phosphorylation of GSK-3α/ß. Furthermore, general anesthetics such as 
pentobarbital and chloral hydrate, both injected intraperitoneally, as well as inhalation of 
halothane vapor increased Ser21/Ser9-phosphorylation of GSK-3α/ß (Li et al., 2005). 
During the last ten years several new insights about neuropsychiatric diseases have 
been gained: Abnormally reduced expression of neurotrophins, such as brain-derived 
neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF), leads to a defect 
of neuroplasticity, and thus imitates the defective morphology in neurodegenerative disorders. 
Besides impaired neurotransmission, this pathology is an additional factor for the genesis of 
mood disorders. As new neurons continually arise in the hippocampus, not only in the 
adolescent but also in the adult human brain (Krishnan and Nestler, 2008; Pittenger and 
Duman, 2008; Wada et al., 2005a), lithium also seems to be an option for curing acute brain 
injuries, such as ischemia, as well as chronic neurodegenerative disorders, such as 
Alzheimer’s disease (Marmol, 2008; Quiroz et al., 2004; Wada et al., 2005a). Indeed, it has 
been shown that lithium or other GSK-3-inhibitors have beneficial effects in the treatment of 
brain injuries, and that in consequence of a traumatic event in the brain, the PKB/GSK-3ß/ß-
catenin-pathway was activated to yield compensatory and preventive effects (Shapira et al., 
2007). 
Lithium has been used since 1970 as a drug against mania, depression, and suicide, 
thus demonstrating its positive effects concerning mood stabilization, behavioral 
improvement, and neurogenesis. Although the cellular mechanism of lithium still remains 
unclear, it has been elucidated that its beneficial effects are consequence of its inhibition of 
GSK-3ß and subsequent accumulation of ß-catenin, which leads to ß-catenin-dependent gene 
transcription (Marmol, 2008; Quiroz et al., 2004; Takahashi-Yanaga and Sasaguri, 2007; 
Wada et al., 2005a; Wada et al., 2005b). Lithium leads to the inhibition of GSK-3, first as a 
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competitive inhibitor of Mg2+ via direct inhibition of the Mg2+-ATP-dependent catalytic 
activity of GSK-3 (Ryves and Harwood, 2001), and second by increase of the Ser21/Ser9-
phosphorylation sites of GSK-3α/ß by a yet not fully clarified mechanism. 
Furthermore, there has been evidence that insulin-like growth-factor-1 (IGF1) and 
IGF2, as well as insulin itself, improve mood (Benedict et al., 2004; Hoshaw et al., 2005; 
Hoshaw et al., 2008; Malberg et al., 2007), memory (Trejo et al., 2007; Trejo et al., 2008), 
neurogenesis (ibid), and angiogenesis (Lopez-Lopez et al., 2004). IGF1 and IGF2 are 
upregulated by antidepressants (Chen and Russo-Neustadt, 2007; Grunbaum-Novak et al., 
2008; Khawaja et al., 2004; Sinha et al., 2005), and IGF1 in turn upregulates BDNF and its 
receptor TrkB (Chen and Russo-Neustadt, 2007; Ding et al., 2006; McCusker et al., 2006). 
Inhibition of GSK-3 by several antimanic drugs, especially lithium, has been 
considered to account for their beneficial effects in bipolar disorders (Gould and Manji, 2005; 
Klein and Melton, 1996). Moreover, inhibition of GSK-3 has been shown to yield 
antidepressant-like effects (Gould et al., 2004; Kaidanovich-Beilin et al., 2004; Redrobe and 
Bourin, 1999). 
Dopamine, a drug applied in Parkinson’s disease and involved in the genesis of 
psychotic symptoms in schizophrenia, regulates GSK-3 via D2 dopamine receptor, ß-arrestin 
2 (ßArr2)/protein phosphatase 2A (PP2A) and PKB (Beaulieu et al., 2009). Antidepressive 
drugs, such as selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase (MAO) 
inhibitors and tricyclic antidepressants, inhibit GSK-3 by increasing its amino-terminal 
phosphorylation in several brain regions (Beaulieu et al., 2008; Li et al., 2004).  
PKB and SGK are in the same way involved in the regulation of behavior (Beaulieu et 
al., 2005; Emamian et al., 2004; Lang et al., 2006b; Lang et al., 2007). PI3K is activated by 
brain-derived neurotrophic factor (BDNF) which has been mainly implicated in the 
pathophysiology and treatment of depression and bipolar disorder (Belzung et al., 1990; Fan 
and Sklar, 2008; Lang et al., 2004; Lang et al., 2005b; Lang et al., 2007). 
Summing up, there is considerable evidence that the GSK-3/ß-catenin pathway plays 
an important role in the pathophysiology of neuropsychiatric diseases and thus represents an 
important target for the treatment of these disorders. The impact of the downstream signaling 
molecules still needs to be investigated as they play a crucial role in neuropsychiatric 
homeostasis. 
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1.6 PDK1- and GSK-3-modified mice as a model for hyperactivity 
1.6.1 PDK1-modified mice 
There is evidence from rodent studies that indicate that the amygdala plays the central role in 
the acquisition and expression of conditioned fear (Maren and Quirk, 2004). Recently, it has 
been demonstrated that brain-derived neurotrophic factor (BDNF) and phosphatidylinositol 3-
kinase (PI3K) are involved in fear learning in the amygdala (Ou and Gean, 2006). Studies in 
humans have largely confirmed hypotheses about fear conditioning that were derived from 
animal studies, where neuroimaging studies demonstrate that the amygdala is critical for 
emotional learning in fear conditioning paradigms (Davis and Whalen, 2001; Maren and 
Quirk, 2004). The BDNF hypothesis of depression and anxiety postulates that a loss of BDNF 
is directly involved in the pathophysiology of depression and anxiety, and its restoration may 
underlie the therapeutic efficacy of antidepressant treatment (Groves, 2007; Martinowich et 
al., 2007). BDNF affects neuronal growth, neurogenesis and memory in a PI3K-dependent 
manner (Atwal et al., 2000; Ou and Gean, 2006), and signals via phosphoinositide-dependent 
protein kinase 1 (PDK1) (Chikahisa et al., 2006). Accordingly, the PI3K signaling pathway 
has been shown to regulate hippocampal proliferation, differentiation, and survival, to 
develop dendrite size and shape, and to induce functional synapses in neuronal cells (Kumar 
et al., 2005; Martin-Pena et al., 2006; Peltier et al., 2007). Both, pharmacological inhibition 
and genetic manipulation of PI3K-dependent signaling demonstrate that PI3K signals via 
PDK1 (Vanhaesebroeck and Alessi, 2000). PDK1 is a direct downstream effector of PI3K 
(ibid), and plays a central role in activating other downstream processes, including cell 
proliferation, survival and differentiation (Mora et al., 2004). On the neurotransmitter level, 
especially serotonin (5-HT) and GABA have been shown to powerfully regulate the 
neuroanatomical circuit that mediates fear in anxiety disorders (Stahl, 2002). To explore the 
impact of PDK1 signaling on transmitter concentrations in amygdala, as well as on behavior, 
gene-targeted mice were analyzed. 
The attempt to create PDK1 knockout mice revealed that embryos die at embryonic 
day 9.5 (Lawlor et al., 2002). These embryos show several abnormalities, such as missing 
somites, forebrain, and neural-crest-derived tissues, whereas their hind- and midbrain 
developed normally (ibid). As the PDK1 knockout mouse is not viable, mice with PDK1 
activity suppressed to around 10% (pdk1hm) (ibid) were used. They are viable and fertile, and 
after insulin injection PKB, S6K and RSK are activated as expected. Discovered differences 
are the smaller size of pdk1hm mice (reduction of 40-50%), and the accordingly reduced organ 
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volumes, whereas the number, nuclear size and proliferation rate of cells were not affected by 
PDK1 deficiency (ibid). Pdk1hm were compared to their age- and sex-matched wild-type 
littermates (pdk1WT). 
 
1.6.2 GSK-3-modified mice 
As shown recently (Prickaerts et al., 2006), transgenic mice overexpressing GSK-3 display 
strikingly increased general locomotor activity and decreased habituation in an open-field test, 
as well as increased acoustic-startle response and reduced immobility in the forced-swimming 
test. That study suggests GSK-3ß-overexpressing mice as a model for hyperactivity that 
reflects the manic phase of bipolar disorder. However, the disadvantage of a generally GSK-
3-overexpressing mouse model lies in elevated PKB levels as a consequence of a more 
pronounced negative feedback in the GSK-3-overexpressing mouse (Prickaerts et al., 2006). 
To avoid this undesirable negative feedback and to obtain mice in which the inhibitory effect 
of insulin on GSK-3 is specifically disrupted but other inhibitory pathways on GSK-3 still 
function, a specific GSK-3 knock-in mouse was created (McManus et al., 2005) (Fig.2). 
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Figure 2: Insulin signaling in the PI3K pathway and its inhibitory effect on GSK-3, both of which are 
abolished in gsk3KI mice 
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Replacement of serine within the PKB phosphorylation site by alanine  
(GSK-3α21A/21A, GSK-3ß9A/9A) renders GSK-3 resistant to inactivation by PKB/SGK 
(McManus et al., 2005). Accordingly, the effect of insulin on muscle glycogen synthase is 
abrogated in knock-in mice carrying these mutations, called gsk3KI (ibid) (Fig.2). On the other 
hand, GSK-3 signaling that is dependent on Wnt is not impaired in those mice (ibid), that 
develop normally and do not show any deficits in development, an effect that is should be 
expected when Wnt signalling is impaired. Besides studies that suggested a similar point of 
action on GSK-3 of both Wnt and PKB/SGK1, Wnt has been shown to inhibit GSK-3 via 
another mechanism than phosphorylation of Ser9 and Ser21 (Ding et al., 2000).  
Mice lacking one allele of the GSK-3ß gene (gsk3ß+/-) showed antidepressant 
behavior, for example by increasing mobility in the forced-swimming test, and had elevated 
levels of ß-catenin in the hypothalamus as well as accelerated Wnt/ß-catenin-dependent gene 
transcription in hippocampus, amygdala, and hypothalamus. Gsk3ß+/- mice thereby mimicked 
treatment with lithium in wild-type mice, regarding both behavioral and biochemical aspects 
(O'Brien et al., 2004).  
Mice with overexpressed ß-catenin showed less depressive behavior, as did mice 
treated with lithium, an observation that suggest that lithium acts via induction of ß-catenin 
expression (Gould et al., 2007). So GSK-3ß seems to be an important mediator of 
antidepressant effects of lithium, offering an additional application for lithium besides control 
of mania and stabilization of mood in patients with bipolar disorder.  
To gain further insight in the pathophysiology of psychiatric diseases and to 
investigate possible new drug targets, the characteristics of mice with gene modification 
related to the PI3K pathway were determined. 
 
1.7 The goal of the studies 
As elaborated above, there is considerable evidence that the PI3K signaling pathway plays an 
important role in the pathophysiology and in the treatment of neuropsychiatric disorders. 
Several mouse models, such as the gsk3+/- mouse, the GSK-3 overexpressing gsk3tg mouse or 
the mouse with overexpressed ß-catenin support the hitherto existing findings that 
therapeutical approaches of neuropsychiatric disorders culminate in GSK-3.  
The novel mouse model resistant to PKB/SGK1-dependent inhibition of GSK-3 
(gsk3KI vs. gsk3WT) offers a new and more specific investigation of GSK-3, namely the 
insulin-dependent influence in psychiatric disorders. The characterization of mice with a 
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hypomorphism of PDK1 (pdk1hm) pursues the speculation that upstream targets of GSK-3 
could be similarly involved in the genesis of neuropsychiatric diseases and exhibit mirror-like 
features. 
Besides longing for deeper understanding of psychiatric disorders and the molecular 
mechanisms that lead to breakdown of the physiological balance of neurotransmitters and 
kinases, the long-run aim is to develop new drugs against diseases, such as schizophrenia, 
Alzheimer’s disease, ADHD and bipolar disorder. Kinases participating in the PI3K pathway 
seem to be a possible target for the development of inhibitors that could be a new hope for 
many patients. 
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2. Materials and Methods 
2.1 Biochemical analysis 
2.1.1 Dissection of the brains and homogenization procedure 
Mice were sacrificed 7 days after the last behavioral experiment. After decapitation, the brains 
were rapidly removed, immediately frozen on dry ice, and stored at –80°C until use. For 
dissection, the frozen brains were placed on a cold plate, providing a temperature between  
–10°C and –12°C. At this temperature, the brain tissue was in a semi-frozen state with well-
preserved anatomical structure. The amygdala/piriform cortex was cut out using the rhinal 
fissure as landmark. The olfactory bulb was dissected along the basis of the frontal cortex. 
Each tissue sample was homogenized by ultrasonication in 40-80 volumes of distilled water.  
For the determination of nerve growth factor (NGF) and brain-derived neurotrophic 
factor (BDNF) protein, 150µl of the homogenate were added to an equal volume of buffer 
containing 0.1M Tris-HCl, pH 7.0, 0.4M NaCl, 0.1% NaN3, and a variety of protease 
inhibitors (“complete”-Protease Inhibitor Cocktail Tablets, Roche Diagnostics GmbH, 
Penzberg, Germany). For the analysis of monoamines and metabolites, 150µl of the 
homogenate were added to an equal volume of 0.2M perchloric acid and centrifuged at 
25,000g for 20min at 4°C. Serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), and the 
catecholamines noradrenaline (NA) and dopamine (DA) were measured in the supernatant 
(23). For amino acid analysis 20µl of the homogenate were added to 80µl methanol and 
centrifuged at 25,000g for 20min at 4°C. The supernatant was diluted 1:30 with distilled 
water.  
 
2.1.2 Determination of NGF and BDNF protein 
Endogenous NGF levels in the thawed homogenates were determined by a fluorometric two-
site enzyme immunoassay (ELISA) which has been described in detail elsewhere (Hellweg et 
al., 1989; Hellweg et al., 2001). The mean recovery of mouse NGF (125pg/ml) added to the 
homogenate ranged from 60% to 90%. NGF content was expressed as equivalents of mouse 
2.5S NGF. The detection limit of the assay was 0.25pg/ml. 
Endogenous levels of BDNF were measured in the thawed homogenates using 
commercial ELISA kits, in principle according to the manufacturer’s instructions (Promega, 
Montréal, Canada), but adapted to the fluorometric technique, and also used for NGF 
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determination (Hellweg et al., 2003; Hellweg et al., 2006). BDNF content was expressed as 
equivalents of recombinant human BDNF. The detection limit of the assay was 1 pg/ml. Each 
sample (namely each tissue dissected and homogenized as described above) was 
consecutively processed for quantification of each neurotrophin, i.e. NGF and BDNF (ibid). 
Determination of recovery, and specific and unspecific neurotrophin binding [the latter 
against mouse IgG1 obtained from MOPC 21 (Mouse IgG1, kappa monoclonal)] involved 
quadruplicate fluorescence determination for each tissue sample. The neurotrophin levels 
were expressed as pg/mg tissue (wet weight). To minimize the influence of unavoidable 
variances between experiments, neurotrophin levels from experimental animals were 
normalized as a percentage of wild-types serving as control, always being included in the 
same experiment (Hellweg et al., 2001).  
 
2.1.3 Determination of monoamines and metabolites 
Analysis of 5-HT and 5-HIAA was performed using high-performance liquid chromatography 
(HPLC) with electrochemical detection (Sperk, 1982). NA and DA were measured by HPLC 
with electrochemical detection after extraction to alumina (Felice et al., 1978) with minor 
modifications (Sperk et al., 1981).  
 
2.1.4 Determination of amino acids 
Glutamate, gamma-aminobutyric acid (GABA), and taurine were determined using methods 
described previously (Piepponen and Skujins, 2001). In brief, amino acids were precolumn 
derivatized with o-phthalaldehyde-2-mercaptoethanol using a refrigerated autoinjector, and 
then separated on a HPLC column (ProntoSil C18 ace-EPS) at a flow rate of 0.6ml/min and a 
column temperature of 40°C. The mobile phase was acetonitrile 50 mmol/ml sodium acetate 
solution pH = 5.7 in a linear gradient from 5% to 21% acetonitrile. Derivatized amino acids 
were detected by their fluorescence at 450nm and excitation at 330nm.  
 
2.1.5 Determination of ACTH and Cortisol levels 
Mice were superficially anesthesized with diethylether (Carl Roth, Karlsruhe, Germany), and 
200-300µl blood was withdrawn by retro-orbital puncture of the eye. The blood was 
centrifuged (Centrifuge 5417R, Eppendorf, Hamburg, Germany) and ACTH and Cortisol 
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levels were determined in the plasma (ACTH-ELISA-Kit, Calbiotech, AC018T, 
Corticosterone ELISA-Kit, DRG Diagnostics, EIA-4164). 
 
2.2 Animals 
All animal experiments were conducted according to the guidelines of the American 
Physiological Society and the German law for the care and welfare of animals, and were 
approved by local authorities. 
 
2.2.1 Study with pdk1 hypomorphic (pdkhm) mice 
The generation and basic properties of pdkhm mice have been described (Lawlor et al., 2002). 
Genotyping was made by PCR on tail DNA, using pdk1 and neo-R-specific primers as 
previously described (Lawlor et al., 2002; Williams et al., 2000). The mice had a mixed 
Sv129 and C57Bl6 background. 
Pdkhm mice were compared to their wild-type littermates (pdkWT) that were obtained 
from a heterozygote breeding, and age and sex were matching in both groups. For the study, 
12 pdkhm mice and 16 pdkWT mice were used with an average age between 4.1 and 10.9 
months. Mice had free access to standard mouse diet (C 1310, Altromin, Lage, Germany) and 
tap water.  
One week before the experiments started, the animals were transferred to the Institute 
of Anatomy in Zurich, where they were singly housed in standard type-2 mouse cages and 
maintained at a 12:12-hour inverted cycle, with lights on between 8 p.m. and 8 a.m. The mice 
were fed a standard chow (Art. 3430, KLIBA NAFAG, Provimi Kliba AG, Kaiseraugst, 
Schweiz, www.kliba-nafag.ch), and tap water and nesting material were again available ad 
libitum.  
The behavioral experiments were performed between 8 a.m. and 8 p.m. Only one type 
of experiment was done on the same day, and the home cage rack was brought to the test 
room at least 30min before the experiment started. The apparatus were cleaned with 70% 
ethanol and water before each animal was tested. Experiments extended over a total time of 6 
weeks, and the average age of the mice was 5.6 months at the beginning and 7.5 months at the 
end of the testing period. 
For data acquisition, animals were video tracked at 4.2 Hz and 576x768 pixel spatial 
resolution, using a Noldus EthoVision 3.0 system (Noldus Information Technology, 
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Wageningen, The Netherlands, www.noldus.com). Raw data were transferred to the public 
domain software Wintrack 2.4 (Wolfer et al., 2001) for further analysis.  
Tests were done in the following order: open-field test, light-dark box (LD-box) test, 
O-maze test, emergence test, object-exploration test, and acoustic-startle response profile. The 
experiments were performed with diffuse indirect room light produced by 440 W bulbs that 
were adjusted to obtain approximately 12 lux in the center of the experimental arena. The LD-
box test was the only exception when full room light was used to yield approximately 500 lux 
in the illuminated compartment. 
Data were analyzed using a two-way factorial ANOVA design, with genotype as 
between subject factor. Where appropriate, the model was complemented by within-subject 
factors to explore the dependence of genotype effects on place, time, and stimulus intensity. 
One-sample t-tests were used to compare group means with hypothesized values.  
Where possible, ANOVA main effects were verified using nonparametric tests which 
produced similar results. Statview version 5.0 (SAS Institute, Cary, North Carolina, 
www.statview.com) was used for all statistical calculations. The software, Sigma Stat, was 
used for the statistical analysis of data concerning neurotrophin and metabolite 
concentrations. For statistical analysis of the biochemical data, the Student’s t-test was 
applied. 
 
2.2.2 Glycogen synthase kinase 3 knock-in (gsk3KI) mice 
The mice were generated, in which the codon encoding Ser9 of the GSK-3ß gene was 
changed to encode nonphosphorylatable alanine (GSK-3ß9A/9A), and, simultaneously, the 
codon encoding Ser21 of the GSK-3α gene was changed to encode nonphosphorylatable 
alanine (GSK-3α21A/21A), thus yielding the GSK-3α/β21A/21A/9A/9A double-knock-in mouse 
(gsk3KI), as described previously (McManus et al., 2005). The mice had a mixed Sv129 and 
C57Bl6 background. 
The mice were compared to appropriate age and sex-matched wild-type mice (gsk3WT). 
As WT littermates and double-knock-in mice GSK-3α/β21A/21A/9A/9A can only be obtained at a 
ratio of 1 in 16 in the same cross, it is impractical to perform a heterozygous breeding. 
Instead, GSK-3α/β21A/21A/9A/9A were interbred with GSK-3α/β21A/21A/9A/9A mice as well as 
GSK-3α/β+/+/+/+ with GSK-3α/β+/+/+/+ littermates derived from a 1-in-16 ratio cross (McManus 
et al., 2005). 
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For all experiments, 11 gsk3WT mice and 11 gsk3KI mice were included in the study. They 
were fed a control diet (C1310, Altromin, Lage, Germany) and had free access to tap water.  
Two months before the experimental period, animals were changed to a 12:12 hour inverted 
cycle, with lights on between 7 p.m. and 7 a.m. To avoid fighting of males, mice were housed 
alone or in groups of maximal 3 mice during the experimental period. 
Behavioral testing occurred between 7 a.m. and 7 p.m. Only one type of experiment 
was done on the same day, and the home cages were brought to the test room at least 30min 
before the experiment started. The equipment was thoroughly cleaned with 70% ethanol and 
water before releasing the animal. Experiments extended over a total of 5.9 weeks, average 
age was 4.5 months at the beginning and 5.8 months at the end of the testing period. 
For data acquisition, animals were video tracked by the camera 302050-SW-KIT-
CAM at a resolution of 0.62 to 0.72-pixel (TSE-Systems, Germany, www.TSE-
Systems.com). Raw data were transferred to Excel® for further analysis.  
Tests were done in the following order: open-field test, LD-box test, O-maze test, 
emergence test, object-exploration test, and forced-swimming test. Experiments were 
performed with diffuse indirect room light produced by dimmable bulbs, adjusted to yield less 
than 30 lux in the center of the experimental arena. The only exception was the LD-box test 
where full room light was switched on. 
Data are provided as means ± SEM, “n” represents the number of independent 
experiments. All data were tested for significance using t-test analysis, and, accordingly, the 
repeated measures ANOVA with time as within-subject factor for habituation. Only results 
with p < 0.05 were considered statistically significant. 
 
The behavioral studies for pdkhm and pdkWT mice were performed at the Institute of Anatomy 
in Zurich, whereas the study that followed with gsk3KI and gsk3WT was done at the Institute of 
Physiology in Tuebingen, and differences in methodology occurred.  
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2.3 Behavioral studies 
The experiments with PDK1-hypomorphic mice have been performed as described in detail 
(Lang et al., 2006b). 
The complete equipment for the study with PDK1-hypomorphic mice was purchased from 
Noldus EthoVision Technology, Wageningen, The Netherlands, www.noldus.com. For 
behavioral studies with GSK-3 knock-in mice, equipment from TSE-Systems, Germany, 
www.TSE-Systems.com was used, and the program VideoMot served for analysis.  
 
2.3.1 Open-field test 
The open-field test is internationally used to measure locomotor and mood-related behavior in 
a quantitative way. The test is also used to analyze anxiety-related behavior. It is based on the 
observation that mice avoid unknown and brightly illuminated areas where there is no 
possibility to hide and retreat. If mice are exposed to such an environment, they find 
themselves in a conflict between anxiety and exploration, as mice are naturally curious 
animals. Besides speed and total distance mice move, giving information about their general 
activity, it is a matter of particular interest which zone of the open-field they prefer. The open-
field is divided into “central” and “peripheral”, and it has been shown that rodents tend to 
avoid open spaces because they prevent the rodents from performing thigmotaxic1 behavior 
(Ramos and Mormede, 1998). It can be concluded that staying in the corners and the border 
area indicates a more anxious behavior, and exploration of the center of the arena points out a 
more active and audacious behavior. Another parameter for activity and curiosity is the 
willingness of the mice to stand on their hind feet while inspecting the environment to 
improve exploration. Such behavior is called “rearing” and is mainly observed in the border 
area towards the wall but also freestanding in the center. 
For the study with pdkhm and pdkWT mice the round open-field arena had a diameter of 
150cm, a white plastic floor, and 35cm high sidewalls made of white polypropylene. Each 
subject was released near the wall and observed for 10min. The same procedure was repeated 
the following day, resulting in a total observation time of 20min (Madani et al., 2003). For 
evaluation, the arena was divided into a center field comprising 50% of the arena surface and 
a 7cm wide wall zone (18% of the surface). The zone between the wall and the center was 
defined as transition zone.  
                                                 
1
 Thigmotaxis is the need for pressure on all sides of your body in order to feel safe. 
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For the study with gsk3KI and gsk3WT mice a quadratic open-field arena was used with 
side lengths of 50cm, a white plastic floor, and 40cm high sidewalls. Each subject was 
released near the wall and observed for 30min (Madani et al., 2003). For evaluation, a border 
with 10cm distance to the wall was considered. Rearing was detected via an infrared light-
beam detector that surrounds the open-field and can be adjusted to the size of the tested 
animal. 
 
2.3.2 Light-dark box test 
The light-dark (LD) box test is the most currently used model to characterize anxious 
behavior in mice. It consists of a dark and safe compartment (one third) and a brightly 
illuminated open and thus aversive area (two-thirds) (Crawley and Goodwin, 1980). The 
apparatus creates a conflict for the mouse, that tends to explore the unfamiliar area, and 
initially wants to avoid the unfamiliar (neophobia). The fraction of time spent in the box is 
seen in correlation to anxiety and depression, whereas the number of transitions and the time 
spent in the illuminated compartment are indices for curiosity and exploration (Bourin and 
Hascoet, 2003). Furthermore, rearing is another important index of activity (Costall et al., 
1989). 
For the study with pdkhm and pdkWT mice, a 20x30cm transparent Perspex chamber 
with a height of 20cm was connected by a 7.5x7.5cm aperture to a 20x15x20cm polyvinyl-
chloride dark box. The chamber was illuminated by direct room light, and each subject was 
released in the illuminated compartment and observed for 5min (Crawley and Goodwin, 
1980). 
For the study with gsk3KI and gsk3WT mice, an infra-red-permeable box made of black 
acrylic plastic (40cm high) was inserted into the open-field, covering 33% of the surface area. 
An aperture of 10x11cm with rounded-down corners led from the light arena to the dark box. 
The experiment was performed under direct room light. Each subject mouse was released in 
the illuminated compartment and observed for 5min (Crawley and Goodwin, 1980).  
 
2.3.3 O-maze test 
The O-maze test is an additional model to investigate anxiety-related behavior. The 
experiment tests the urge of mice to discover an unknown area and their instinct to protect 
themselves from a dangerous situation. Mice usually avoid dangerous areas, presented by the 
open sectors of the O-maze, and prefer safe places, such as the zone that is protected by walls. 
II  Material and Methods 
 32 
Usually they override their anxiety after a certain time because of curiosity. Time spent in the 
open sectors, as well as general activity, was evaluated (Konig et al., 1996). Other important 
measures are whether and how quickly the mice dare to leave the original protecting arm and 
enter the opposing area, and the frequency of head dips over the edge of the open sectors 
(Shepherd et al., 1994). It is distinguished between so-called “protected head dips”, where the 
back of the mouse is between the protecting walls, and “unprotected head-dips”, where the 
mouse completely stands in an open sector. 
For the study with pdkhm and pdkWT mice, a 5.5cm wide annular runway made of grey 
plastic was constructed as O-maze. The outer diameter measured 46cm and was placed inside 
the above open-field arena, 40cm above the floor. The two opposing 90° closed sectors were 
protected by 16cm high inner and outer walls of grey polyvinyl-chloride, while the remaining 
two open sectors had no walls. Animals were released in one of the closed sectors and 
observed for 10min (Konig et al., 1996; Lang et al., 2006b). 
The apparatus used for the study with gsk3KI and gsk3WT mice was made of grey plastic, 
the closed sectors were protected by 11cm-high inner and outer walls, and the two open sectors 
had a border of 5mm (Fig.3). 
 
  
Figure 3: O-maze used for behavioral studies with gsk3KI and gsk3WT mice 
 
2.3.4 Emergence test 
The emergence test complements the open-field test. By contrast, the emergence test reduces 
anxiety in mice by providing a safe and well-known enclosure within the open-field test 
(Dulawa et al., 1999). As in the open-field test, though, the emergence test also serves the 
purpose of characterizing exploratory and anxious behavior but with the additional option for 
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the mouse to back out of danger into a familiar environment. The main interest is the time 
spent in or near the familiar home box. 
For the study with pdkhm and pdkWT mice, frames of non-reflective aluminium with a 
height of 37cm were used to divide the open-field into four square arenas that measured 
50x50cm, allowing observation of four animals at the same time. Each arena had a 12x8x4cm 
plastic home box, with an aperture of 8x4cm that was positioned in a corner at 5cm from the 
nearest wall, with the aperture of the box facing away from the wall. A day prior to the 
experiment, the home-box was put into the cage of each test subject, and in preparation for the 
actual experiment the same box was introduced into the arena and fixed with adhesive tape. 
Each subject was observed for 30min. 
 For the study with gsk3KI and gsk3WT mice, an infra-red-permeable box, which had 
been previously in the home cage of the mouse during more than 24 hours, was inserted into 
the open-field arena. The home box had a base area of 9x10cm, with two apertures (3cm 
length, 3.5cm height with rounded down corners) on the long side.  
 
2.3.5 Object-exploration test 
The object-exploration or novel-object test complements the open-field and emergence tests. 
A novel-object is introduced into the arena, and the behavior of the mouse is observed. 
Approach towards the object because of curiosity and exploration counters the avoidance of 
the unknown stimulus because of fear. Besides speed and total distance mice move, giving 
information about their general activity, parameters of interest include time spent in the home 
box area, visits into the home box, as well as time exploring the novel-object.  
 For the study with pdkhm and pdkWT mice, the procedure was modified (Dulawa et al., 
1999). Arenas were the same as for the emergence test, but without the home box. A 12x4cm 
semi-transparent 50ml falcon tube was used as novel-object, positioned vertically in the center 
of the arena and fixed with adhesive tape. Each subject was observed for 30min in the empty, 
cleaned arena. Then, the novel-object was introduced and observation continued for another 
30min. 
For the study with gsk3KI and gsk3WT mice, the experimental set-up was supplementary 
modified: the novel-object was put in addition to the familiar home box to investigate the 
exploratory behavior of the mouse in a partly familiar environment where it has the possibility 
to retreat. The mouse was first observed for 30min in the open-field including the home box. 
Afterwards, a falcon tube was added to the area and fixed with adhesive tape. The mouse was 
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then observed for another 30min, and the contact with the nose on the falcon tube was taken as 
criterion to analyze the reaction on a novel-object.  
 
2.3.6 Acoustic-startle response 
The startle response is an unconditioned reflexive response to a sudden unexpected stimulus, 
such as a flash of light, a loud noise (acoustic-startle reflex), or a quick movement near the 
face. Humans usually move away from the stimulus, contract their muscles, and blink, the 
latter by far the most conspicuous involuntary movement (Castellote et al., 2007). It has been 
shown in rats that the latency of the acoustic-startle reflex, measured from the onset of the 
tone to the beginning of the electromyographic response in the hindleg, is 8ms (Davis et al., 
1982).  
For the study with pdkhm and pdkWT mice, a Hamilton-Kinder SM100 startle monitor 
system was used (www.hamiltonkinder.com, Poway, CA). The animal restrainer had the 
measures 3.8x8.8cm and was made of clear Perspex. An adjustable ceiling prevented the 
animal from rearing. The restrainer was put on a sensing plate, which carried a piezoelectric 
accelerometer at its bottom. The unit was attached to a heavy metallic base plate by means of 
four mounting pins, then enclosed in a sound-attenuated ventilated cabinet with the 
dimensions 29x29x18cm. The loudspeaker was located 22cm above the animal, and produced 
white-noise pulses. A microcomputer interface controlled the loudspeaker and performed an 
analog-to-digital (A/D) conversion of the signals from the accelerometer. Signal calibration 
was done using a Newton impulse calibrator. Sound levels were verified by a digital sound 
level meter (Radio Shack). The background noise level inside the closed cabinet was 
maintained at 70dB. Each test mouse was placed in the restrainer and left undisturbed for 5min 
before the session began. In total, 66 trials were performed. Nine different sound levels were 
used: 64, 68, 72, 76, 80, 90, 100, 110, and 120dB (Paylor and Crawley, 1997). Each stimulus 
lasted 40ms and was presented 6 times in a pseudorandom order such that each sound level 
occured once within a block of 9 trials. The series started and ended with 6 presentations each of 
the 120dB stimulus. The average intertrial interval was 15s (ranging from 10 to 20s). The startle 
response was recorded for 250ms while measuring the response every 1ms, starting with the 
onset of the startle stimulus. The maximum amplitude was used as the dependent variable. 
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2.3.7 Forced-swimming test 
The forced-swimming test is extensively utilized in neurobiological research and within 
pharmaceutical companies that operate antidepressant drug discovery programs (Willner, 
2005). Such tests give conclusions about the depressive behavior of rodents. The animal is 
forced to swim in a situation where there is no escape. After an initial period of vigorous 
activity, the animal will reduce its movements to a minimum just to keep its head above the 
water. The so-called “floating behavior” is defined as the absence of direct movements of an 
animal’s head and body. It has been shown not only that chronic mild stress (CMS) increase 
(Willner, 2005) but also that antidepressant drugs decrease (Porsolt et al., 1977; Prickaerts et 
al., 2006) the time of floating. 
Gsk3KI and gsk3WT mice where placed in a glass of water with temperature between  
24 and 26°C. The diameter of the glass was 20cm, and the mouse was placed in the water 
without being able to touch the bottom. Each subject was observed during 6min, and the time 
it spent without movement was recorded. After the experiment, the mice were dried under an 
infrared heat lamp before being returned to their home cage. 
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3. Results 
3.1 Behavioral studies with pdk1hm mice 
3.1.1 Body and brain weight 
Pdk1hm mice appeared healthy, but they were considerably smaller than their wild-type 
littermates. Body weight was significantly lower in pdk1hm mice than in pdk1WT mice 
(p<0.0001, Table 1), which was the case also for fresh brain weight (p<0.0001, Table 1). The 
weight of the amygdala as well as of the olfactory bulb of pdk1hm mice was significantly less 
in pdk1hm mice than in pdk1WT mice (Table 1). The relation between reduction of brain and 
that of body weight was not significantly different between pdk1hm mice and pdk1WT mice 
(Table 1). 
 
Table 1: Body weigth and weight of brain structures of pdk1hm and pdk1WT mice 
Parameter WT (n=16) PDK1 (n=12) Significance 
Average body weight 30.20 ± 0.85 g 23.69 ± 0.68 g p<0.0001 
Fresh brain weight 0.51 ± 0.004 g 0.38 ± 0.003 g p<0.0001 
Brain / body weight 1.62 ± 0.05 % 1.70 ± 0.06 % n.s. 
Amygdala weight 23.63 ± 0.51 mg/1000µl 17.73 ± 0.58 mg/1000µl p<0.0001 
Olfactory bulb weight 24.18 ± 0.55 mg/1000µl 17.68 ± 0.39 mg/1000µl p<0.0001 
 
The removal of the brains of the pdk1hm and pdk1WT mice was done in cooperation with and 
principally by Giovanni Colacicco (Ph.D.), Institute of Anatomy, University of Zurich and 
Department of Biology, ETH Zurich. 
 
3.1.2 Open-field test 
In the open-field test, no clear differences in spontaneous behavior were detected between 
genotypes. Pdk1hm mice tended to be less active than pdk1WT mice during the first 5min on 
each day, but the time course of activity is statistically indistinguishable between the 
genotypes (Fig.4A). Both groups avoided the center and transition zones in favor of the wall 
zone, and pdk1hm mice showed a trend to prefer the wall zone of the arena slightly more 
(Fig.4B).  
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Figure 4: Speed and time spent in different zones of pdk1WT and pdk1hm mice in the open-field test 
A: Arithmetic means ± SEM (n = 12-16 each group) of speed in the open-field during the first and second 5 
minutes on the first and second day;  
Day 1: 0-5min: pdk1WT: 7.78 ± 0.71m/min, pdk1hm: 6.24 ± 0.74m/min, n.s.; 5-10min: pdk1WT: 9.20 ± 0.54m/min, 
pdk1hm: 9.18 ± 0.64m/min, n.s  
Day 2: 0-5min: pdk1WT: 8.77 ± 0.82m/min, pdk1hm: 7.60 ± 1.08m/min, p<0.05; 5-10min: pdk1WT: 10.27 ± 
0.64m/min, pdk1hm: 10.02 ± 0.70m/min, n.s.  
B: Arithmetic means ± SEM (n = 12-16 each group) of time spent in center, transition and wall zone; centre: 
pdk1WT: 17.83 ± 0.99%, pdk1hm: 14.15 ± 1.77%; transition: pdk1WT: 20.79 ± 1.07%, pdk1hm: 17.9 ± 1.30%; wall: 
pdk1WT: 61.38 ± 1.43%, pdk1hm: 67.96 ± 2.65%; n.s. 
 
3.1.3 Light-dark (LD) box test 
In the LD-box, both pdk1WT and pdk1hm mice preferred the box to the illuminated 
compartment, without significant differences between genotypes (Fig.5). Light-dark 
transitions were significantly less frequent in pdk1hm mice than in pdk1WT mice (p>0.006), 
which points to a decreased activity of pdk1hm mice. The number of aborted emergencies, i.e. 
when the mouse looks out of the box but decides not to leave it, instead to return into the dark 
compartment, was decreased in pdk1hm mice (p<0.061). The latency to the first rearing was 
significantly increased in pdk1hm mice (p<0.026), indicating a more anxious behavior of 
pdk1hm mice. 
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Figure 5: Time that pdk1WT and pdk1hm mice spent in the dark compartment of the LD-box  
Arithmetic means ± SEM (n = 12-16 each group) of time spent in the dark. pdk1WT: 66.26 ± 3.99%, pdk1hm: 
73.26 ± 5.35%; n.s. 
 
3.1.4 O-maze test 
In the O-maze test, both genotypes strongly avoided the open sectors. Pdk1hm mice spent more 
time on the closed sector than did pdk1WT mice, which preferred to stay in the transition zone 
(Fig.6A). The number of unprotected head dips was not different between pdk1hm mice and 
pdk1WT mice, but pdk1hm mice performed fewer protected head dips, and thus displayed less 
risk assessment at the transition between closed and open sectors (Fig.6B). 
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Figure 6: Time that pdk1WT and pdk1hm mice spent in different zones of the O-maze and number of head 
dips 
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A: Arithmetic means ± SEM (n = 12-16 each group) of time spent in open, transition, and closed sectors; open: 
pdk1WT: 9.45 ± 1.39%, pdk1hm: 7.72 ± 1.16%; n.s.; transition: pdk1WT: 53.0 ± 2.27%, pdk1hm: 43.76 ± 2.27%; 
p<0.0148; closed: pdk1WT: 37.55 ± 2.51%, pdk1hm: 48.51 ± 3.11%; p<0.0224 
B: Arithmetic means ± SEM (n = 12-16 each group) of number of unprotected and protected head dips; 
unprotected: pdk1WT: 0.60 ± 0.16x/min, pdk1hm: 0.52 ± 0.13x/min; n.s.; protected: pdk1WT: 2.14 ± 0.23x/min, 
pdk1hm: 1.48 ± 0.19x/min; p<0.0337 
 
3.1.5 Emergence test  
In the emergence test, pdk1hm mice showed the same initial activity as did pdk1WT mice, but 
female pdk1hm mice habituated less than did their wild-type litttermates (Fig.7A). Both groups 
avoided the center zone and preferred to stay in the zone surrounding the home box (Fig.7B). 
Pdk1hm mice tended to spent more time inside the home box than did pdk1WT mice (6.09 ± 
1.40% vs. 4.49 ± 0.63%; n.s.). 
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Figure 7: Activity and time that pdk1WT and pdk1hm mice spent in different zones in the emergence test 
A: Arithmetic means ± SEM (n = 12-16 each group) of total activity in the emergence test in bins of 10min;  
0-10min: pdk1WT: 5.07 ± 0.33m/min, pdk1hm: 5.25 ± 0.21m/min; 10-20min: pdk1WT: 4.51 ± 0.30m/min, pdk1hm: 
4.97 ± 0.32m/min; 20-30min: pdk1WT: 4.26 ± 0.29m/min, pdk1hm: 4.77 ± 0.33m/min; n.s. 
B: Arithmetic means ± SEM (n = 12-16 each group) of time spent in centre, wall and home zone; centre: pdk1WT: 
23.7 ± 2.0%, pdk1hm: 24.33 ± 1.63%; n.s.; wall: pdk1WT: 37.97 ± 2.22%, pdk1hm: 36.25 ± 1.82%; home: pdk1WT: 
38.52 ± 2.43%, pdk1hm: 39.57 ± 2.02%; n.s. 
 
 
III  Results 
 40 
3.1.6 Object-exploration test 
In the period before the insertion of the object, pdk1hm mice did not habituate, becoming, 
however, more active when the novel-object was present (Fig.8A). Irrespective of genotype, 
the mice showed significant exploratory activity towards the object (Fig.8B). 
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Figure 8: Object-exploration of pdk1WT and pdk1hm in the object-exploration test 
A: Arithmetic means ± SEM (n = 12-16 each group) of activity in the object-exploration test in bins of 10min 
before and during the presence of a novel-object (m/min): 
before insertion of the object: 0-10min: pdk1WT: 4.78 ± 0.36m/min, pdk1hm: 4.99 ± 0.38m/min, n.s.; 10-20min: 
pdk1WT: 4.23 ± 0.32m/min, pdk1hm: 4.84 ± 0.41m/min, n.s.; 20-30min: pdk1WT: 3.84 ± 0.33m/min, pdk1hm: 4.93 ± 
0.41m/min, p<0.05  
during the presence of the object: 0-10min: pdk1WT: 4.19 ± 0.37m/min, pdk1hm: 5.48 ± 0.49m/min, p<0.05;  
10-20min: pdk1WT: 3.41 ± 0.36m/min, pdk1hm: 4.72 ± 0.45m/min, p<0.05; 20-30min: pdk1WT: 3.25 ± 0.29m/min, 
pdk1hm: 4.4 ± 0.46m/min, p<0.05 
B: Arithmetic means ± SEM (n = 12-16 each group) of exploratory movements towards the object (x/min): 
before insertion of the object: 0-10min: pdk1WT: -0.006 ± 0.004x/min, pdk1hm: -0.003 ± 0.006x/min, n.s.;  
10-20min: pdk1WT: 0.005 ± 0.005x/min, pdk1hm: 0.009 ± 0.007x/min, n.s.; 20-30min: pdk1WT: 0.001 ± 
0.003x/min, pdk1hm: -0.006 ± 0.005x/min, n.s.  
during the presence of the object: 0-10min: pdk1WT: 0.284 ± 0.038x/min, pdk1hm: 0.231 ± 0.023x/min, n.s.;  
10-20min: pdk1WT: 0.1 ± 0.02x/min, pdk1hm: 0.117 ± 0.02x/min, n.s.; 20-30min: pdk1WT: 0.085 ± 0.018x/min, 
pdk1hm: 0.075 ± 0.015x/min, n.s. 
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3.1.7 Acoustic-startle response 
In the acoustic-startle response profile, the response profile of pdk1hm mice tended to be 
shifted to the right, indicating a threshold increase (Fig.9).  
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Figure 9: Startle response amplitude to stimuli of 68, 72, 76, 80, 90, 100, 110, and 120dB 
* Significant genotype effect at individual SPL after correction for multiple comparisons according to false 
discovery rate control procedure of Benjamini and Hochberg 
 
3.1.8 Neurotransmitter concentrations 
In the amygdala, pdk1hm mice had, as compared to pdk1WT mice, lower 5-HT concentrations 
(Table 2, p = 0.034) and an increased 5-HT turnover, as indicated by the molar ratio of 5-
HIAA, a metabolite of 5-HT, to 5-HT (Table 2, p = 0.046). The NA content was increased in 
pdk1hm mice (Table 2, p = 0.017). GABA and taurine concentrations in the amygdala were 
lower in pdk1hm mice than in pdk1WT mice (Table 2, p = 0.015, p= 0.023), whereas glutamate 
and DA were not significantly different between genotypes. BDNF and NGF concentrations 
in the amygdala were not significantly different between pdk1hm and pdk1WT mice (Table 2).  
In the olfactory bulb, 5-hydroxyindoleacetic acid concentrations were higher in pdk1hm 
mice than in pdk1WT mice (Table 3, p = 0.047), but 5-HT concentrations were not significantly 
different between pdk1hm and pdk1WT mice. NA concentration was significantly greater in 
pdk1hm than in pdk1WT mice (Table 2, p = 0.019, p = 0.021). Glutamate and DA concentrations 
in the olfactory bulb were not significantly different between pdk1hm and pdk1WT mice. Also 
BDNF and NGF concentrations in the olfactory bulb were not significantly different between 
genotypes.  
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Table 2: Neurotransmitter and neurotrophin concentrations in the amygdala. Data are presented as 
means ± SEM. The levels of 5-HT, 5-HIAA, NA, DA, NGF and BDNF are expressed as pg/ml tissue, the 
levels of GABA, glutamate and taurine as pmol/mg tissue.  
 
Substance WT (n=16) PDK1 (n=12) Significance 
5-HT 1122.3 ± 36.6 pg/ml 1019.4 ± 20.7 pg/ml p = 0.034 
5-HIAA 805.6 ± 38.0 pg/ml 885.7 ± 62.9 pg/ml n.s. 
5-HIAA/5-HT 0.668 ± 0.032 0.805 ± 0.063 pg/ml p = 0.046 
NA 383.5 ± 19.5 pg/ml 461.5 ± 23.8 pg/ml p = 0.017 
DA 285.2 ± 29.8 pg/ml 258.9 ± 39.5 pg/ml n.s. 
GABA 3.1 ± 0.1 pmol/mg 2.85 ± 0.05 pmol/mg p = 0.015 
Glutamate 11.94 ± 0.26 pmol/mg 12.1 ± 0.5 pmol/mg n.s. 
Taurine 12.8 ± 0.2 pmol/mg 11.87 ± 0.35 pmol/mg p = 0.023 
NGF 5.51 ± 0.52 pg/ml 5.6 ± 0.4 pg/ml n.s. 
BDNF 20.2 ± 2.4 pg/ml 24.4 ± 3.3 pg/ml n.s. 
 
Table 3: Neurotransmitter and neurotrophin concentrations in the olfactory bulb. Data are presented as 
means ± SEM. The levels of  5-HT, 5-HIAA, NA, DA, NGF and BDNF are expressed as pg/ml tissue, the 
levels of GABA, glutamate and taurine as pmol/mg tissue. 
 
Substance WT (n=16) PDK1 (n=12) Significance 
5-HT 561.6 ± 16.9 pg/ml 614.0 ± 31.1 pg/ml n.s. 
5-HIAA 796.7 ± 25.5 pg/ml 945.9 ± 75.6 pg/ml p = 0.047 
5-HIAA/5-HT 1.314 ± 0.039 1.481 ± 0.078 pg/ml n.s. 
NA 195.3 ± 12.0 pg/ml 243.1 ± 12.0 pg/ml p = 0.010 
DA 248.5 ± 12.1 pg/ml 263.4 ± 17.6 pg/ml n.s. 
GABA 9.54 ± 0.19 pmol/mg 8.87 ± 0.18 pmol/mg p = 0.019 
Glutamate 8.0 ± 0.2 pmol/mg 7.9 ± 0.3 pmol/mg n.s. 
Taurine 18.66 ± 0.37 pmol/mg 17.84 ± 0.94 pmol/mg p = 0.021 
NGF 10.54 ± 1.19 pg/ml 11.75 ± 1.94 pg/ml n.s. 
BDNF 8.71 ± 1.24 pg/ml 8.87 ± 1.59 pg/ml n.s. 
 
The preparation of the brains and the determination of transmitter concentrations was done in 
cooperation with and principally by the laboratory group of Professor Undine Lang (M.D.), 
Department of Psychiatry and Psychotherapy, Charité University Medicine Berlin, Campus 
Mitte, Berlin, and Professor Heide Hörtnagl (M.D.), Department of Pharmacology, Charité 
University Medicine Berlin, Campus Mitte, Berlin. 
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3.2 Behavioral studies with gsk3KI mice 
3.2.1 Open-field test 
In the open-field test, both speed (Fig.10A) and total distance traveled (Fig.10B) were 
significantly increased in gsk3KI mice when compared to gsk3WT mice, and all subjects 
showed significant habituation, i.e. a parallel decrease in distance moved over time, 
independently of genotype. While generally preferring the border area, the fractions of time 
spent within the border zone and at the center, respectively, were similar in gsk3KI and gsk3WT 
mice (Fig.11A), whereas the distance moved in the border zone was significantly elevated in 
gsk3KI mice (Fig.11B). Moreover, the duration (Fig.12A) and number (Fig.12B) of rearings at 
the border of the open-field were significantly greater in gsk3KI mice than in gsk3WT mice, as 
was the ratio between time of and number of rearing (Fig.12C). This indicates a more curious 
and active phenotype of gsk3KI mice compared to gsk3WT mice. Focusing on the center, gsk3KI 
mice did not perform significantly more or fewer rearings than did gsk3WT mice, and the 
number of visits of the center and the distance traveled in the center were tendentially 
elevated in gsk3KI mice (Table 4). 
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Figure 10: Speed and distance traveled of gsk3WT and gsk3KI mice in the open-field 
A. Arithmetic means ± SEM (n = 10-11 each group) of speed in the open-field during the first, second and third 
10 minutes. gsk3WT: 4.86 ± 0.55cm/s, 3.83 ± 0.47cm/s, 2.93 ± 0.35cm/s vs. gsk3KI: 7.11 ± 0.57cm/s, 5.95 ± 
0.82cm/s, 5.08 ± 0.74cm/s 
B. Arithmetic means ± SEM (n = 10-11 each group) of distanced traveled in the open-field during the first, 
second and third 10 minutes. gsk3WT: 29.12 ± 3.32m, 23.01 ± 2.85m, 17.55 ± 2.09m, gsk3KI: 42.69 ± 3.42m, 
35.68 ± 4.92m, 30.46 ± 4.43m 
* indicates significant difference between genotypes (repeated measures ANOVA, p < 0.05) 
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Figure 11: Time of and distance moved of gsk3WT and gsk3KI mice in the border zone of the open-field 
A. Arithmetic means ± SEM (n = 10-11 each group) of time spent (%) in the border zone of the open-field. 
gsk3WT: 88.03 ± 3.2%, gsk3KI: 89.81 ± 2.11%; no significant difference between genotypes 
B. Arithmetic means ± SEM (n = 10-11 each group) of distance moved (m) in the border zone of the open-field. 
gsk3WT: 54.87 ± 4.62%, gsk3KI: 90.75 ± 8.42%; p=0.001 
* indicates a significant difference between genotypes (t-test, p < 0.05) 
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Figure 12: Time of and number of rearings of gsk3WT and gsk3KI mice in the border zone of the open-field 
A. Arithmetic means ± SEM (n = 10-11 each group) of time of rearings (min) in the border zone of the open-
field. gsk3WT: 6.87 ± 0.92min, gsk3KI: 15.02 ± 1.79min; p=0.0054 
B. Arithmetic means ± SEM (n = 10-11 each group) of number of rearings in the border zone of the open-field. 
gsk3WT: 197.27 ± 20.86min, gsk3KI: 296.2 ± 19.98min; p=0.003 
* Indicates a significant difference between genotypes (t-test, p < 0.05) 
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Table 4: Performance of gsk3WT and gsk3KI mice in the open-field 
Behavioral element gsk3WT mice gsk3KI mice p-value 
No. of rearings in center 35.27 ± 12.55 50.1 ± 13.38 n.s. 
Time of rearings in center 1.39 ± 0.55 min 1.88 ± 0.57 min n.s. 
Ratio time/no. rearing in center 2.1 ± 0.18 s 2.04 ± 0.18 s n.s. 
No. of visits of the center 78.0 ± 17.89 94.0 ± 17.46 n.s. 
Distance traveled in center 14.81 ± 3.9 m 18.08 ± 3.98 m n.s. 
 
3.2.2 Light-dark box test 
In the light-dark box test, both genotypes preferred to stay in the box (78.5% in gsk3KI mice vs. 
87.4% in gsk3WT mice, no significant difference between genotypes). Gsk3KI mice entered the 
dark box significantly more often than did gsk3WT mice (Fig.13A), and, as in the open-field 
test, gsk3KI mice performed significantly more rearings than did gsk3WT mice, both in the dark 
box and in the illuminated compartment (Fig.13B and 13C). The average duration of a rearing 
was similar in both genotypes and reached a ratio from 1.46 to 2.17s/rearing (Table 5). 
Concerning the intensity of transitions, gsk3KI mice visited the entrance area more often 
(Fig.14A), spent more time (Fig.14B) and traveled a longer distance in the entrance area 
(Fig.14C). In general, gsk3KI mice traveled a significantly longer distance than did gsk3WT mice 
(Table 5). 
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Figure 13: General performance of gsk3WT and gsk3KI mice in the light-dark box 
A. Arithmetic means ± SEM (n = 11 each group) of number of visits into the box. gsk3WT: 9.18 ± 1.37, gsk3KI: 
14.82 ± 1.26; p=0.007 
B. Arithmetic means ± SEM (n = 11 each group) of number of rearings in box. gsk3WT: 18.27 ± 3.02, gsk3KI: 
44.45 ± 2.79; p=3.3*10-6 
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C. Arithmetic means ± SEM (n = 11 each group) of number of rearings in light area, gsk3WT: 2.91 ± 1.07, 
gsk3KI: 11.0 ± 2.36; p=0.005 
* Indicates a significant difference between genotypes (t-test, p < 0.05) 
 
Table 5: Performance of gsk3WT and gsk3KI mice in the light-dark box 
Behavioral element gsk3WT mice gsk3KI mice p-value 
Time of rearings in the box 26.76 ± 4.82 s 87.96 ± 7.71 s 0.0000015 
Time of rearings in the light 4.48 ± 1.75 s 23.85 ± 6.49 s 0.009 
Ratio time/no. rearing in the box 1.43 ± 0.04 s 1.95 ± 0.08 s 0.0000053 
Ratio time/no. rearing in the light 1.44 ± 0.15 s 1.90 ± 0.21 s n.s.2 
Distance traveled in center 2.04 ± 0.50 m 4.48 ± 0.65 m 0.007 
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Figure 14: Performance of gsk3WT and gsk3KI mice in the transition area of the light-dark box 
A. Arithmetic means ± SEM (n = 11 each group) of number of visits of the transition area. gsk3WT: 10.82 ± 
1.82, gsk3KI: 19.45 ± 1.99; p=0.004 
B. Arithmetic means ± SEM (n = 11 each group) of time spent in the transition area. gsk3WT: 11.57 ± 2.26s, 
gsk3KI: 18.76 ± 2.28s; p=0.037 
C. Arithmetic means ± SEM (n = 11 each group) of distance traveled in the transition area. gsk3WT: 54.81 ± 
11.28cm, gsk3KI: 93.06 ± 11.53cm; p=0.028 
* Indicates a significant difference between genotypes (t-test, p < 0.05) 
 
 
 
                                                 
2
 Only 8 of 11 gsk3WT mice performed rearings in the illuminated compartment. 
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3.2.3 O-maze test 
In the O-maze test, gsk3KI mice spent significantly more time (Fig.15A) and traveled a larger 
distance (Fig.15B) in the open, unprotected area than did gsk3WT mice. The number of 
protected head dips, performed while the back of the mouse was between the protecting walls, 
was not different between the genotypes (Fig.16A). However, in the unprotected area, gsk3KI 
mice looked into the deep significantly more often than did gsk3WT mice; so-called 
unprotected head dips were increased in gsk3KI mice (Fig.16B). This indicates that gsk3KI mice 
are more prepared to take a risk than gsk3WT mice. Similar to what had been observed in the 
open-field test, both the total distance traveled and speed were significantly larger in gsk3KI 
mice than in gsk3WT mice (Table 6). As many as 8 out of 11 gsk3KI mice and only one out of 
11 gsk3WT mice visited the opposite area, whereas there was no significant difference in the 
time it took the mice to enter the opposite protected area. Gsk3KI mice spent significantly less 
time in the area of origin than did gsk3WT mice (Table 6), stressing once more their more 
curious and active behavior. 
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Figure 15: Time and distance traveled of gsk3WT and gsk3KI mice in the open area of the O-maze 
A. Arithmetic means ± SEM (n = 11 each group) of time in the open area. gsk3WT: 8.40 ± 1.81%, gsk3KI: 16.96 
± 1.87%; p=0.004 
B. Arithmetic means ± SEM (n = 11 each group) of distance traveled in the open area. gsk3WT: 1.66 ± 0.52m, 
gsk3KI: 4.13 ± 0.42m; p=0.0015 
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Figure 16: Number of protected and unprotected head dips in the O-maze 
A. Arithmetic means ± SEM (n = 11 each group) of protected head dips. gsk3WT: 20.09 ± 1.78, gsk3KI: 19.27 ± 
2.99; n.s 
B. Arithmetic means ± SEM (n = 11 each group) of unprotected head dips. gsk3WT: 1.82 ± 0.92, gsk3KI: 8.73 ± 
0.83; p=0.000019 
 
Table 6: Performance of gsk3WT and gsk3KI mice in the O-maze 
Behavioral element gsk3WT mice gsk3KI mice p-value 
Total distance traveled 15.0 ± 1.32 m 19.7 ± 1.31 m 0.020 
Speed 2.5 ± 0.22 cm/s 3.28 ± 0.22 cm/s 0.020 
Latency to enter opposite arm 2.59 min 3.26 ± 0.55 min n.s. 
Time in area of origin 88.21 ± 4.73 % 69.86 ± 4.87 % 0.014 
 
3.2.4 Emergence test 
In the emergence test, a well-known home box was put into the open-field, and the mouse was 
observed for 30min. Both gsk3KI and gsk3WT mice spent more than 60% of the time in the 
home box area (Table 7). The distance moved in this area and the number of visits into the 
home box tended to be higher in gsk3KI mice (Table 4), indicating enhanced activity of gsk3KI 
mice in a familiar environment. Both speed and distance moved were significantly elevated in 
gsk3KI mice in the first 10min (Fig.17A and 17B). Gsk3KI mice then showed a significantly 
higher rate of habituation than that of gsk3WT mice. 
 
 
 
III  Results 
 49 
Table 7: Performance of gsk3WT and gsk3KI mice in the emergence test 
Behavioral element gsk3WT mice gsk3KI mice p-value 
Time in home box area 60.94 ± 8.32 % 64.33 ± 6.63 % n.s. 
Distance in home box area 26.06 ± 1.51 m 30.51 ± 1.59 m n.s. 
Visits in box 84.0 ± 9.26 109.2 ± 14.79 n.s. 
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Figure 17: Speed and total distance traveled of gsk3WT and gsk3KI mice in the emergence test  
A. Arithmetic means ± SEM (n = 10 each group) of speed in the emergence test during the first, second and third 
10 minutes. gsk3WT: 3.68 ± 0.34cm/s, 3.04 ± 0.35cm/s, 2.60 ± 0.32cm/s; gsk3KI: 5.75 ± 0.35cm/s, 3.69 ± 
0.55cm/s, 2.94 ± 0.49cm/s 
B. Arithmetic means ± SEM (n = 10-11 each group) of distanced traveled in the emergence test during the first, 
second and third 10 minutes. gsk3WT: 22.08 ± 2.01m, 18.22 ± 2.09m, 15.58 ± 1.89m; gsk3KI: 34.51 ± 2.07m, 
22.15 ± 3.32m, 17.62 ± 2.93m 
* Indicates significant difference between genotypes (repeated measures ANOVA, p < 0.05) 
 
3.2.5 Novel-object test 
In the novel-object test, the first 30min of the experiment were identical to the emergence test. 
Then, a 50ml falcon tube was put as a novel-object in the arena and the mouse was observed 
for another 30min to see the reaction to a novel-object within an otherwise familiar 
environment, the home box. In general, mice preferred to stay in the home box, both in the 
absence and in the presence of the novel-object (Table 8). Gsk3KI mice tended to visit the 
novel-object more often and to spend more time exploring the object (Table 5), which can be 
interpreted as increased curiosity. The latency to the first visit of the object tended to be 
decreased in gsk3KI mice, indicating a faster approach to unknown objects and less fear 
(Fig.18A). Furthermore, the time spent in the corners far away from the object was 
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significantly increased in gsk3WT mice, which can be interpreted as avoidance of the object 
(Fig.18B). Speed and total distance traveled decreased over time in both gsk3WT and gsk3KI 
mice, without significant effects between genotypes. 
 
Table 8: Performance of gsk3WT and gsk3KI mice in the novel-object test 
Behavioral element gsk3WT mice gsk3KI mice p-value 
Time in home box in absence of object 53.4 ± 8.7 min 69.4 ± 7.0 min n.s. 
Time in home box in presence of object 55.3 ± 9.3 min 72.2 ± 8.6 min n.s. 
Visits of object 12.55 ± 7.01 45.18 ± 24.21 n.s. 
Time spent exploring the object 7.36 ± 4.70 s 23.95 ± 11.11 s n.s. 
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Figure 18: Reaction of gsk3WT and gsk3KI mice on a novel-object 
A: Arithmetic means ± SEM (n = 11 each group) of latency to the first visit of the novel-object. gsk3WT: 4.79 ± 
2.21min, gsk3KI: 1.99 ± 0.96min; n.s. 
B: Arithmetic means ± SEM (n = 11 each group) of time spent in corners during presence of the novel-object. 
gsk3WT: 3.78 ± 1.15min, gsk3KI: 1.02 ± 0.35min; p=0.033 
 
3.2.6 Forced-swimming test 
In the Forced-swimming test, gsk3KI mice spent significantly less time floating than did 
gsk3WT mice (Fig.19), which indicates a less depressive behavior. 
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Figure 19: Time floating of gsk3WT and gsk3KI mice in the forced-swimming test 
Arithmetic means ± SEM (n = 7 each group) of time spent floating. gsk3WT: 1.51 ± 0.24min, gsk3KI: 0.12 ± 
0.05min; p=0.000096  
 
3.2.7 Body weight, food and fluid intake, and hormones 
Body weight and food and fluid intake were determined during the behavioral studies. There 
was no difference in body weight, while food and fluid intake were significantly increased in 
gsk3KI mice (Fig.20A and 20B). To determine the function of the hypothalamic-pituitary-
adrenal (HPA) axis, cortisol and adrenocorticotropic hormone (ACTH) levels were measured 
in gsk3WT and gsk3KI mice. ACTH was significantly elevated in gsk3WT mice (Fig.21A), and 
cortisol tended to be increased (Fig.21B). 
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Figure 20: Food and fluid intake of gsk3WT and gsk3KI mice  
A: Arithmetic means ± SEM (n = 11 each group) of food intake. gsk3WT: 2.51 ± 0.16g, gsk3KI: 3.56 ± 0.12g; 
p=0.000043 
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B: Arithmetic means ± SEM (n = 11 each group) of food intake. gsk3WT: 2.63 ± 0.10ml, gsk3KI: 5.42 ± 0.23g; 
p=4.43x10-10 
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Figure 21: ACTH and cortisol levels in plasma of gsk3WT and gsk3KI mice  
A: Arithmetic means ± SEM (n = 11-13 each group) of ACTH levels. gsk3WT: 265.03 ± 39.0pg/ml, gsk3KI: 
124.5 ± 29.3pg/ml; p=0.0077 
B: Arithmetic means ± SEM (n = 7-8 each group) of cortisol levels. gsk3WT: 356.29 ± 74.74pg/ml, gsk3KI: 
187.74 ± 39.15pg/ml; p=0.078, n.s. 
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4. Discussion 
4.1 Study with pdk1hm mice 
Behavioral examination of the pdk1hm phenotype revealed increased anxiety behavior in 
several different tests, i.e. open-field test, light-dark box test, and O-maze test, all of which 
was accompanied by changes in GABA, NA, and 5-HT concentrations in the amygdala and 
olfactory bulb.  
As reported earlier (Lawlor et al., 2002), body weight in pdk1hm mice was significantly 
reduced, and this was proportional to decreases in brain weight. This decrease appeared to be 
primarily due to decreased cell volume rather than reduction of cell number (ibid). Among 
other factors, cell volume and brain metabolism are determined by cellular uptake of amino 
acids (Lang et al., 1998). The influence of PDK1 deficiency on brain neurotransmitter 
abundance and anxiety behavior could thus be related to altered amino acid transport. PDK1 
activates the serum and glucocorticoid inducible kinase (SGK1) and protein kinase B 
(PKB)/Akt isoforms (Lang and Cohen, 2001), which in turn have been shown to regulate a 
wide variety of transporters (Lang et al., 2006a). Previous experiments in pdk1hm mice indeed 
revealed a decreased activity of glucose transporters (Artunc et al., 2006) and amino acid 
transporters (Rexhepaj et al., 2006). Moreover, an increased fluid and food intake has been 
reported in pdk1hm mice, while urinary excretion of glutamate and tryptophan, but not 
serotonin, is increased in pdk1hm mice (ibid). However, plasma concentrations of these 
cerebrally relevant amino acids (glutamate, tryptophan, glycin) in pdk1hm mice did not differ 
significantly from those of pdk1WT mice (ibid). Similarly, dopamine and glutamate 
concentrations in amygdala and olfactory bulb were not significantly different between 
pdk1hm and pdk1WT mice (Tables 1 and 2).  
The behavioral experiments revealed that pdk1hm mice differed from wild-type 
littermates in several behavioral measurements related to anxiety and exploration. 
Hypoactivity of pdk1hm mice is demonstrated by the tendency to initially move less distance 
in the open-field test (Fig.4), by less frequent light-dark transitions in the light-dark box 
experiment (Fig.5), and by the observation that pdk1hm mice spent more time inside the 
protected sectors and performed fewer protected head dips in the O-maze (Fig.6). In the 
emergence test (open-field with home box), pdk1hm mice spent more time inside the home 
box, but showed normal exploratory activity while outside the box (Fig.7-8). This observed 
normal exploratory activity in the emergence test does not fit to increased anxiety behavior, 
IV  Discussion 
 54 
but might be explained by agitation (Arban et al., 2005; Gould et al., 2007; Shaltiel et al., 
2008). 
Increased anxiety behavior in pdk1hm mice can be linked to decreased activation of the 
PI3K/Akt pathway, which has been shown to contribute to mechanisms of synaptic plasticity 
and memory consolidation by promoting cell survival and synapse number (Horwood et al., 
2006; Martin-Pena et al., 2006). After activation of PI3K, PDK1 is activated and leads to 
phosphorylation of PKB/Akt. Activated PKB/Akt phosphorylates intracellular substrates and 
promotes cell survival by inhibiting apoptosis through several targets, including Forkhead 
transcription factors and mammalian target of rapamycin (Martin-Pena et al., 2006). One of 
the essential functions of PKB/Akt is the phosphorylation of glycogen synthase kinase (GSK-
3), causing its inactivation and thereby the activation of cAMP response element binding 
protein (CREB) (Peltier et al., 2007). Decreased CREB function in the central amygdala was 
suspected to be involved in anxiety behavior (Pandey et al., 2003; Pandey et al., 2005), and a 
decreased CREB phosphorylation after BDNF antisense infusion was found (Pandey et al., 
2006), possibly attributable to decreased PI3K activity. Recently, it was shown that fear 
learning in the amygdala involves BDNF and PI3K activation (Ou and Gean, 2006).  
A role for the PI3K signaling cascade in anxiety behavior is plausible, as several 
factors influencing anxiety behavior act via PI3K. Recently, it was demonstrated in vivo that 
anxiolytic cannabinoids activate the PI3K/Akt pathway and negatively regulate GSK-3ß 
activity in the mouse brain (Ozaita et al., 2007). Also, insulin-like growth factor-1 (IGF-1) 
and estrogen have been shown to disrupt anxiety behavior and to activate PI3K (Garcia-
Segura et al., 2006; Malberg et al., 2007; Toufexis et al., 2006). Moreover, exercise, with its 
well-known anxiolytic properties, activates PI3K pathway (Chen and Russo-Neustadt, 2005; 
Salmon, 2001). BDNF has also been related to anxiety behavior (Lang et al., 2005b; Lang et 
al., 2005a) and fear conditioning, especially in the amygdala (Chhatwal et al., 2006; Opazo et 
al., 2003; Ou and Gean, 2006), and BDNF acts via PI3K (Rattiner et al., 2004; Sanna et al., 
2002). In this context, we expected a compensatory upregulation of BDNF and NGF in 
pdk1hm mice which was, however, not observed (Tables 2 and 3). It should be kept in mind 
that PI3K signaling in pdk1hm mice is not completely abrogated, while PDK1 activity is 
suppressed by up to 80-90% (Lawlor et al., 2002). The residual PDK1 activity may be 
sufficient to prevent upregulation of BDNF. In any case, the findings of increased anxiety 
associated with deficient PI3K signaling suggest that BDNF could influence anxiety at least in 
part via a PI3K-dependent mechanism.  
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Moreover, several factors regulating PI3K activity might converge and exert additive 
effects, or, if absent, increase vulnerability. In line with this hypothesis, heterozygous 
neuroregulin-1 mice are more sensitive to behavioral effects of cannabinoids than are wild-
type mice (Boucher et al., 2007). Additive genetic effects of BDNF and 5-HT transporters are 
dependent on estrogen modulation, so estrogen seems to compensate BDNF deficiency 
regarding behavior and brain monoamine levels (Ren-Patterson et al., 2006). Moreover, 
running exercise- and antidepressant-induced increases in growth and survival-associated 
signaling molecules are IGF-dependent (Chen and Russo-Neustadt, 2007).  
Interestingly, the increased anxiety behavior in pdk1hm mice was accompanied by a 
significant decrease in GABA, taurine and 5-HT in the amygdala, suggesting an involvement 
of these neurotransmitters in the determination of behavioral disturbances (Table 2). 
Moreover, 5-HT turnover was increased in the amygdala and seemed to be increased in the 
olfactory bulb, as well, suggested by increased concentrations of 5-HIAA (Tables 2 and 3). 
Furthermore, in the olfactory bulb a decrease in GABA and taurine was observed (Table 3). In 
both examined brain regions NA concentrations were increased (Tables 2 and 3).  
A large body of evidence from rodent and human neuroimaging studies indicates that 
the amygdala plays a critical role in the acquisition and expression of fear behavior (Davis 
and Whalen, 2001; Maren and Quirk, 2004), which may explain that neurotransmitter changes 
in anxious pdk1hm mice occur in this brain region. The olfactory bulb has been implicated in 
anxiety behavior, too (Wang et al., 2007). Olfactory bulbectomy has been suggested as an 
animal model for comorbid anxiety and leads to hyperexcitability of amygdala neurons 
(Shibata and Watanabe, 1994; Wang et al., 2007). Indeed, olfactory information converges in 
the amygdala, where the involvement of PI3K signaling has recently been observed in fear 
learning (Ou and Gean, 2006).  
A decreased GABA concentration in amygdala and olfactory bulb fits well to the 
concept that GABA is the principal inhibitory neurotransmitter in the mammalian brain, and 
its receptors are key control elements of anxiety states. This concept is based on the anxiolytic 
properties of benzodiazepines, which act as allosteric GABA receptor agonists (Nemeroff, 
2003). Recently, first evidence for a control of GABAergic function through PI3K-mediated 
pathways has been reported (Salgado et al., 2007). Moreover, the additional observation of 
decreased taurine in both brain areas, as observed in pdk1hm mice, is in line with the role of 
taurine as an anxiolytic-like amino acid after single and repeated administrations and its 
modulation of amygdala-associated anxiety (Kong et al., 2006; McCool and Chappell, 2007). 
IV  Discussion 
 56 
5-HT is believed to be the most relevant neurotransmitter in mediating anxiety (Murphy et al., 
1999). The promotor region of the serotonin transporter gene features a long and a short 
variant, whereas persons with one or two short forms are more likely to become depressive 
after a stressful event than are people with two long alleles (Caspi et al., 2003). Therefore, 
decreased 5-HT concentrations in the amygdala, as found in our pdk1hm mice, might well 
explain increased anxiety behavior. The amygdala is overactive in patients with anxiety 
disorders, and chronic administration of 5-HT reuptake inhibitors (SSRIs) normalizes 
amygdalar activity, representing the treatment of choice in anxiety disorders (Muller et al., 
2007; Rauch, 2003; Sheline et al., 2001).  
The observed decreases of taurine concentrations in amygdala and olfactory bulb of 
pdk1hm mice are similarly in line with increased anxiety behavior in pdk1hm mice. In rats, 
taurine microinjections in the amygdala have been shown to reduce anxiety behavior (McCool 
and Chappell, 2007), and an anxiolytic effect of taurine (i.p.) was also observed in mice 
(Kong et al., 2006).  
The present study did not address the mechanisms underlying the influence of PDK1 
on neurotransmitter levels. It is noteworthy, though, that PI3K signaling has been shown to 
participate in the regulation of GABA transport (de La Paz et al., 2002; Malyala et al., 2008), 
and the taurine transporter (Cruz-Rangel et al., 2008; de La Paz et al., 2002; Franco et al., 
2001; Pasantes-Morales and Franco, 2002). Kinases activated by PDK1 include the serum and 
glucocorticoid inducible kinase (SGK) and protein kinase B (PKB/Akt) isoforms, which have 
been shown to regulate a wide variety of channels and transporters, including glutamate 
transporters and glutamate receptors (Green et al., 2008; Hills et al., 2006; Ishiki and Klip, 
2005; Lang et al., 2006a; Luo and Sun, 2007; Maier et al., 2006; Sato et al., 2007; Sen et al., 
2003; Strutz-Seebohm et al., 2007; Tessier and Woodgett, 2006; Whiteman et al., 2002). 
Moreover, SGK and PKB phosphorylate and, thus, inhibit glycogen synthase kinase GSK-3ß 
(Wyatt et al., 2006), which plays a pivotal role in the regulation of behavior (Gould and 
Manji, 2005; Lang et al., 2007; Rowe et al., 2007). Reduced locomotion reminiscent of the 
PDK1 hypomorphic mouse was observed in SGK3-deficient mice (Lang et al., 2006b).  
Finally, unpublished commercial observations revealed that patients who received a 
PDK1 inhibitor within their anti-cancer treatment had depressive symptoms as side effects. 
This finding supports our hypothesis that PDK1 plays an important role in anxiety and mood- 
related disorders.  
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4.2 Study with gsk3KI mice 
The study that characterizes the behavior of gsk3KI mice revealed a role of PKB/SGK-
dependent regulation of GSK-3 in the control of behavior. Mice carrying a mutation of GSK-
3α in which the codon encoding Ser21 was changed to encode a nonphosphorylatable Ala 
residue (GSK-3α 21A/21A), and at the same time carrying a mutation of GSK-3β in which 
the codon encoding Ser9 was changed to encode a nonphosphorylatable Ala residue (GSK-3ß 
9A/9A), are expected to be resistant to PKB/SGK-dependent regulation of GSK-3 (McManus 
et al., 2005). According to the present observations, mice carrying the PKB/SGK-resistant 
GSK-3 mutants (gsk3KI) are significantly more active and curious than were the 
corresponding wild-type mice (gsk3WT) in several behavioral settings. The enhanced 
locomotor activity has been considered a correlate of mania (Lyon, 1999; Machado-Vieira et 
al., 2004). 
In line with behavioral parameters, the function of the HPA axis is changed between 
the phenotypes: In gsk3KI mice ACTH was significantly decreased and cortisol tended to be so 
(Fig.21). A hypothesis has been formulated, relating aberrant stress hormone regulation to 
causality of depression, which suggests that the amount of ACTH and cortisol is significantly 
higher among depressive patients (Thomson and Craighead, 2008). Moreover, the hypothesis 
was raised that antidepressants act through normalization of these HPA changes, and several 
antidepressant treatment strategies have been developed targeting the HPA axis, e.g. cortisol 
biosynthesis inhibitors, glucocorticoid receptor antagonists, corticotrophin releasing factor 
receptor antagonists, and vasopressin receptor antagonists (Thomson and Craighead, 2008). 
According to a previous study, plasma concentrations and urinary excretions of aldosterone 
were similarly altered in gsk3KI mice (Boini et al., 2008). Moreover, several functional 
parameters were different between gsk3KI and corresponding wild-type mice (ibid). It must be 
kept in mind that at least in theory, the metabolic effects of dysregulated peripheral GSK-3 
may influence behavior by altering plasma metabolite, electrolyte, and hormone 
concentrations. 
 In general, mice are expected to prefer secure and safe places, represented by the 
border of the open-field test, the dark compartment in the light-dark box experiment, the 
closed, tunnel-like sections in the O-maze test, and the home box in the emergence and novel-
object test. Gsk3WT and gsk3KI mice comply with those expectations, as both genotypes prefer 
the mentioned secure zones (Zorner et al., 2003). However, several parameters revealed 
increased locomotor activity in gsk3KI mice, as measured by increased speed and total 
distance traveled in the open-field test, light-dark box test, O-maze test, and emergence test. 
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The hyperactivity and increased curiosity of mice might also be evidenced by the increased 
number of entrances into the dark box (Belzung et al., 1990), as well as the increased time 
spent in the entrance area of the box. However, the light-dark transitions might also just 
reflect generally enhanced activity, and the elevated dwell time in the entrance area could also 
be seen as increased risk assessment of gsk3KI mice. 
The O-maze test is an established model for investigating anxiety-like behavior. 
Inherently, mice would avoid passing a dangerous way, as simulated by the open areas. The 
risk assessment of gsk3KI mice, however, did not prevent them from entering the opposite 
area. Gsk3KI mice showed a clearly enhanced risk behavior while spending more time and 
traveling a longer distance on the open areas, as well as performing more unprotected head 
dips. This behavior points to reduced anxiety. The fact that gsk3KI mice spent less time in the 
origin arm points to enhanced curiosity and preference to explore the environment, instead of 
their benefiting from the security in this area (Shepherd et al., 1994). Moreover, reduced 
anxiety in gsk3KI mice is represented by an increased number and duration of rearings in the 
open-field test and in the light-dark box experiment (Calabrese, 2008). 
The emergence test and novel-object test have to be seen from another point of view, 
as the mouse is inserted into an environment which is partly familiar due to the well-known 
home box. During the emergence test, speed and total distance traveled were enhanced in 
gsk3KI mice, whereas there was no difference observed during the novel-object test. 
Apparently, the environment influences the behavior of mice and must be considered in the 
interpretation of anxiety-related behavior. The insertion of a novel-object emphasized the loss 
of fear and the increased curiosity of gsk3KI mice. Compared to gsk3WT mice, gsk3KI mice are 
clearly hyperactive in the open-field test, light-dark box test, and O-maze test. In the 
emergence test hyperactivity seems less pronounced, and in the object-exploration test there 
was no hyperactivity. This suggests that hyperactivity is novelty induced, being most 
pronounced when mice are placed in a completely new environment.  
The enhanced activity of the gsk3KI mice is reminiscent of the hyperactivity of 
transgenic mice overexpressing GSK-3 (gsk3tg) (Prickaerts et al., 2006). Unlike gsk3KI mice, 
gsk3tg mice also showed deficient habituation. Conversely, the stimulating effect of 
amphetamines on locomotor activity is decreased in heterozygote GSK-3 deficient mice 
(Beaulieu et al., 2004), and reversed by lithium and with specific GSK-3 inhibitors (Gould et 
al., 2004).  
Increased curiosity, decreased anxiety, decreased immobility in the forced-swimming 
test, increased activity, and decreased stress hormone levels in gsk3KI mice point to a 
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depression-resistant phenotype. However, disinhibition of PI3K might lead to manic behavior, 
which is not common. Hypomanic states are often observed following depressive episodes 
and antidepressant treatment, which could result from an activation of PKB by antidepressant 
strategies. Indeed, antimanic treatment strategies might involve PKB-dependent regulation of 
GSK-3, which has been shown by several antimanic drugs (clozapine, olanzapine, lithium, 
and valproate) (Aubry et al., 2009; Gould and Manji, 2005; Klein and Melton, 1996). 
Moreover, all of these medications show mood stabilizing properties and long-term phase 
prophylactic properties, which also might involve GSK-3 regulation. 
Overexpression of GSK-3 in the striatum was followed by upregulation of PKB 
expression and downregulation of the expression of PPP2R3A, a regulatory subunit of the 
PKB-inactivating phosphatase PP2A (Prickaerts et al., 2006). Those effects were expected to 
inhibit GSK activity and thus to mitigate the effects of GSK-3 overexpression (ibid). In gsk3KI 
mice, this negative feedback is disrupted, as similarly elevated PKB levels in gsk3KI and 
gsk3WT mice after injection of insulin demonstrated (McManus et al., 2005). So, the PI3K 
activity is normal in gsk3KI mice, leading to a more specific phenotype than is seen in the 
mouse model with generally overexpressed GSK-3. The unrestrained GSK-3 activity in gsk3KI 
mice renders those mice an ideal model for the in vivo testing of GSK-3 inhibitors.  
PKB and GSK-3 are further thought to participate in the enhanced locomotion of 
gene-targeted mice lacking the dopamine transporter DAT (Beaulieu et al., 2004; Beaulieu et 
al., 2005). As shown earlier (Boini et al., 2008), food and fluid intake were markedly 
enhanced in gsk3KI mice as compared to gsk3WT mice, pointing to PKB/SGK-dependent 
regulation of GSK-3 in the control of food and fluid uptake. Typically, food intake is 
markedly changed in bipolar patients, and increased food intake might be compensated by 
increased activity in gsk3KI. Moreover, disorders of food intake may parallel psychiatric 
diseases, such as bipolar disorder and schizophrenia (Foulon, 2003; Kishi and Elmquist, 2005; 
Krishnan, 2005). PKB-dependent signaling in the hypothalamus is considered to mediate the 
food intake-lowering effect of insulin (Niswender et al., 2003). This signaling may be 
disrupted in the gsk3KI mice. PKB/SGK-dependent signaling is further required for the effect 
of insulin on glycogen synthase (Cohen and Goedert, 2004; McManus et al., 2005). 
Accordingly, the effect of insulin on muscle glycogen synthase is absent in gsk3KI mice 
(McManus et al., 2005). It would be interesting to explore whether behavioral effects of 
hyperinsulinism are related to PKB/SGK-dependent regulation of GSK-3.  
Interestingly, clozapine and olanzapine, which act on GSK-3 (Rowe et al., 2007), have 
been shown to induce type 2 diabetes mellitus and metabolic syndrome in schizophrenic and 
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bipolar patients (Van Winkel et al., 2008). Moreover, patients with schizophrenia and bipolar 
disorder are particularly prone to develop obesity and type 2 diabetes mellitus (Newcomer, 
2006), disorders considered to involve modulation of GSK-3 (Medina and Castro, 2008). 
 Besides insulin, brain-derived neurotrophic factor BDNF (Corominas et al., 2007; Lim 
et al., 2008) activates the PI3 kinase pathway (Elliott et al., 2005), and is thus expected to 
inhibit GSK-3ß activity. BDNF has in turn been implicated in bipolar disorders (Castren and 
Rantamaki, 2008; Fan and Sklar, 2008; Kapczinski et al., 2008; Kloos et al., 2008; Serretti 
and Mandelli, 2008) and schizophrenia (Lu and Martinowich, 2008; Pillai, 2008).  
The study with GSK-3 knockin mice did not attempt to identify the cerebral structures 
involved in the altered behavior of gsk3KI mice. However, in the study with PDK1-
hypomorphic mice, behavior opposite to that of gsk3KI mice was displayed, and such mice 
showed significantly decreased GABA and taurine concentrations and significantly increased 
NA levels in the amygdala and olfactory bulb, as well as significantly decreased 5-HT levels 
in the amygdala.  
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5. Conclusions 
This study with pdk1hm mice revealed that decreased PI3K signaling may provoke anxiety 
behavior, accompanied by alternations of neurotransmitter concentrations in the amygdala and 
olfactory bulb that play an important role in anxiety-related diseases and depression. The 
finding that pdk1hm mice show an anxious and hypoactive phenotype implicates a role of the 
PI3K pathway in anxiety behavior. Thus, decreased PI3K signaling in pdk1hm mice might be 
an animal model for increased anxiety and depression.  
Mice with a modification of GSK-3 that leads to insensitivity to the inhibitory action 
of PKB and SGK are characterized by altered food and fluid intake, as well as hyperactivity, 
which can be interpreted as manic-like behavior. Moreover, the mutation leads to decreased 
immobility in the forced-swimming test, and decreased activity of the HPA axis, both 
indicators of “anti-depressive” behavior. Thus, PKB/SGK-dependent regulation of GSK-3 
activity might participate in the pathophysiology and treatment of bipolar disorders, and 
gsk3KI mice can be seen as an animal model for psychiatric diseases, such as bipolar disorder 
and schizophrenia. 
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6. Summary 
To investigate the impact of the phosphatidylinositol-3 kinase (PI3K) pathway on psychiatric 
diseases, two mouse models with genetic modifications of the PI3K pathway served for 
behavioral studies.  
On the one hand, there is the PDK1-hypomorphic mouse (pdk1hm) that is characterized 
by a residual activity of the 3-phosphoinositid-dependent protein kinase-1 (PDK1) of only 
around 10%. A complete knockout of PDK1 is impossible because of embryonic mortality of 
the offspring. Various different established models used in behavior research of rodents 
demonstrated that the pdk1hm mouse features anxious behavioral patterns. Furthermore, 
biochemical analysis of brain structures indicated anxious and depressive characteristics of 
the pdk1hm mouse. The amygdala, an important organ for the formation of anxiety, exhibited 
decreased concentrations of gamma-aminobutyric acid (GABA), serotonin (5-HT), and taurin, 
as well as elevated levels of noradrenalin (NA). GABA is an important inhibitory 
neurotransmitter, and anxiety resolving medications, such as benzodiazepines, act as agonists 
on GABA receptors. Serotonin is an important mediator of fear, as medications used in the 
treatment of depression have proven: So-called serotonin-reuptake-inhibitors (SSRIs) increase 
serotonin levels and lead to improved symptoms in patients with major depressive disorders. 
Taurine has anxiety resolving effects, as demonstrated in animal experiments employing 
injections of taurin. NA is a neurotransmitter of the central nervous system, on which 
antidepressants act in a like manner, mitigating the symptoms of depressive people via an 
increase of NA concentration. The olfactory bulb is linked to anxious behavior, too. Its 
sensory information converges in the amygdala where the influence of PI3K was observed 
recently. The olfactory bulb showed, as did the amygdala, decreased concentrations of GABA 
and taurine, and elevated levels of NA.  
The study in pdk1hm mice emphasizes the impact of the PI3K pathway in psychiatric 
diseases. With its characteristic phenotypical and biochemical attributes, the pdk1hm mouse 
can be used as a model for psychiatric diseases, such as anxiety disorders and depression. 
On the other hand, investigations were made in a mouse in which the glycogen 
synthase kinase-3 (GSK-3) was genetically modified so that it was no more inhibitable via 
protein kinase B (PKB/Akt) and serum- and glucocorticoid-inducable protein kinase (SGK). 
Thus, GSK-3 is resistant to the inhibitory properties of insulin. The so-called gsk3KI mice 
demonstrated a hyperactive and audacious behavior in comparion to corresponding wild-type 
mice in several behavioral settings. The increased activity of gsk3KI mice can be associated 
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with manic episodes in psychiatric diseases, such as schizophrenia and bipolar disorders. The 
HPA axis is elevated in depressive patients, whereas gsk3KI mice show a decreased HPA axis, 
which suggest a phenotype opposite to the depressive pdk1hm mouse. Another characteristic of 
the gsk3KI mouse is increased food intake, reminiscent of disturbed-eating behavior in patients 
with bipolar disorder. Different neuroleptics, amongst them clozapine, olanzapine, and 
lithium, inhibit GSK-3 and thus act on the PI3K pathway. As insulin inhibits GSK-3 via the 
PI3K pathway, it is not surprising that those medications lead to diabetes as well as metabolic 
syndrome.  
With its action via the PI3K pathway, insulin exerts a determining influence on 
behavior. When the effect of insulin is attenuated, as expressed in the pdk1hm mouse, anxious 
and depressive behavior is the consequence. However, when its effect is intensified, as can be 
seen in the gsk3KI mouse, hyperactivity and increased risk assessment are observed, which can 
be compared to manic episodes in mentally disordered people.  
Consequently, the pdk1hm mouse describes an animal model for anxiety and 
depression, whereas the gsk3KI mouse represents an animal model for schizophrenia and 
bipolar disorders.  
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7. Zusammenfassung 
Um die Bedeutung des Phosphatidylinositol 3-kinase (PI3K)-Signalwegs bei psychischen 
Krankheiten zu untersuchen, wurden Verhaltensstudien an zwei Mausmodellen durchgeführt, 
die genetische Veränderungen des PI3K-Signalwegs aufzeigen.  
Zum einen handelt es sich um die PDK1-hypomorphe Maus (pdk1hm), bei der die  
3-Phosphoinositid-abhängige Proteinkinase-1 (PDK1) nur noch eine Restaktivität von  
ca. 10% aufweist. Eine komplette Ausschaltung der PDK1 ist aufgrund embryonaler 
Mortalität des Nachwuchses nicht möglich. Die Pdk1hm-Maus weist ängstliche 
Verhaltensmuster auf, wie in verschiedenen etablierten Modellen der Verhaltensforschung an 
Nagern gezeigt werden konnte. Ebenso wiesen biochemische Untersuchungen von 
Gehirnstrukturen auf ängstlich-depressive Eigenschaften der Pdk1hm-Maus hin. Die 
Amygdala, die ein wichtiges Organ bei der Entstehung von Angst darstellt, wies erniedrigte 
Konzentrationen von µ-Aminobuttersäure (GABA), Serotonin (5-HT) und Taurin und eine 
erhöhte Noradrenalin (NA)-Konzentration auf. GABA ist der bedeutendste inhibitorische 
Neurotransmitter und angstlösende Medikamente wie Benzodiazepine greifen als Agonisten 
am GABA-Rezeptor an. Serotonin ist ein wichtiger Mediator von Angst, was inbesondere 
Medikamente, die bei Depression angewendet werden, zeigen: Sogenannte Serotonin-
Wiederaufnahme-Inhibitoren (SSRIs) erhöhen den Serotonin-Spiegel und führen zu 
verbesserten Symptomen bei depressiven Patienten. Taurin hat angstlösende Effekte wie 
Injektionen mit Taurin im Tierversuch zeigen konnten. NA ist ein Neurotransmitter des 
Zentralen Nervensytems, an dem ebenfalls Antidepressiva angreifen und durch eine Erhöhung 
der NA-Konzentration die Symptome depressiver Menschen lindern.  
Der Riechkolben, auch Bulbus olfactorius genannt, steht ebenso in Zusammenhang 
mit ängstlichem Verhalten. Seine Information läuft in der Amygdala zusammen, wo kürzlich 
der Einfluss von PI3K beobachtet wurde. Der Bulbus olfactorius wies wie die Amygdala 
verringerte Konzentrationen von GABA und Taurin und eine erhöhte NA-Konzentration auf.  
Die Studie an der Pdk1hm-Maus unterstreicht die Bedeutung des PI3K-Weges bei 
psychischen Erkrankungen und die Pdk1hm-Maus kann mit ihren charakteristischen 
phenotypischen und biochemischen Merkmalen als ein Modell für psychische Krankheiten 
wie Angststörungen und Depression verwendet werden. 
 Zum anderen wurden Untersuchungen an einer Maus durchgeführt, bei der die 
Glykogensynthase-Kinase-3 (GSK-3) genetisch so verändert wurde, dass sie nicht mehr durch 
die Proteinkinase B (PKB/Akt) und Serum- und Glukokorticoid-induzierbare Kinase (SGK) 
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gehemmt werden kann und somit resistent gegenüber der inhibitorischen Wirkung von Insulin 
ist. Die sogenannte Gsk3KI-Maus zeigte in mehreren Verhaltensversuchen einen hyperaktiven 
Phänotyp und risikofreudigeres Verhalten im Vergleich zu den entsprechenden Wildtyp-
Mäusen. Die gesteigerte Aktivität der Gsk3KI-Maus kann in Zusammenhang mit manischen 
Phasen, wie sie bei den psychischen Krankheiten Schizophrenie und bipolaren Störungen 
auftreten, gebracht werden. Die HPA-Achse ist bei depressiven Patienten erhöht, wogegen die 
Gsk3KI-Maus eine erniedrigte HPA-Achse aufweist, was ebenfalls auf einen Phänotyp der 
Maus schließen lässt, der dem depressiven der Pdk1hm-Maus entgegen gesetzt ist. Ein weiteres 
Kennzeichen der Gsk3KI-Maus ist eine erhöhte Futteraufnahme, was an gestörtes Essverhalten 
bei Menschen mit bipolaren Störungen erinnert. Verschiedene Neuroleptika, darunter 
Clozapin, Olanzapin und Lithium, wirken inhibitorisch auf GSK-3 und greifen damit am 
PI3K-Weg an. Da Insulin über den PI3K-Weg die GSK-3 hemmt, überrascht es nicht, dass 
diese Medikamente zu Typ-2 Diabetes und Metabolischem Syndrom führen können.  
Insulin hat mit seiner Wirkung über den PI3-Kinase-Weg einen entscheidenden 
Einfluss auf das Verhalten. Ist seine Wirkung abgeschwächt, wie es bei der Pdk1hm-Maus zum 
Ausdruck kommt, ist ängstliches und depressives Verhalten die Folge. Ist die Insulin-
abhängige Wirkung dagegen verstärkt, wie man bei der Gsk3KI-Maus erkennen kann, bei der 
die hemmende Wirkung von Insulin aufgehoben wurde, können Hyperaktivität und 
gesteigerte Risikobereitschaft beobachtet werden, die mit manischen Phasen in psychisch 
erkrankten Menschen vergleichbar sind.  
Die Pdk1hm-Maus stellt somit ein Tiermodell für Ängstlichkeit und Depression dar, 
während die Gsk3KI-Maus als Tiermodell für Schizophrenie und Bipolare Störungen 
herangezogen werden kann.  
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